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Abstract 
Background: The discovery of cell free fetal DNA has opened a new door for non-invasive 
prenatal screening and diagnosis. Other cell free nucleic acids, like microRNAs, may also be of 
value in detecting fetal anomalies. miRNAs (small non-coding RNAs) control developmental 
processes and may therefore be useful as biomarkers for fetal abnormalities and placental 
function. We aimed to develop the laboratory skills for reliable analysis of cell free miRNA and to 
collect some pilot data looking at variation in cell free fetal miRNA expression with fetal 
abnormality. 
Methods: Optimisation studies were conducting collecting blood from normal pregnancies into 
three types of collection tubes (EDTA, STRECK and CITRATE) and keeping samples at 4OC or 
room temperature for time intervals ranging from 4 to 96 hours. Six miRNAs, previously defined 
as being placental specific, were measured using qRT-PCR. Samples were spiked with cell-miR-
39 to allow normalisation. Further comparative studies were made between pregnancies 
affected by fetal abnormality and controls. 
Results: Samples from 14 normal pregnancies (mean 21.3 weeks’ gestation) were used for the 
optimisation experiments. There was very significant (up to 100 fold) variation in expression of 
all miRNAs between control specimens. Although there were no statistical significant differences 
in relative expression of miRNA between blood tubes, temperature or time of storage, there 
were trends suggesting that either STRECK tubes held at room temperature or EDTA tubes 
stored at 4OC showed less miRNA variation. Two miRNAs (miR-517 and miR-526) previously 
described as being placental specific could not be detected in any samples. Three miRNAs (miR-
518, miR-520 and miR-525) that were previously described as being placental specific were also 
detected in plasma of three non-pregnant women; miR-525 appeared to be significantly up-
regulated in pregnancy. Only one miRNA (miR-516) appeared to be both present and specific to 
pregnancy. miRNA expression from 16 normal (mean GA 22.8 weeks), 15 chromosomally 
abnormal (mean GA 13.6 weeks), 6 cardiac anomalies (mean GA 20.3 weeks) and 4 neural tube 
defects (mean GA 17.3 weeks) were compared. No significant differences in the relative 
expression of these six miRNAs were seen between control and anomalous pregnancies with the 
exception of significant up-regulation of miR-520 in two fetuses with hypoplastic left heart 
syndrome.  
Conclusion: Optimisation studies suggest that cell free miRNAs are best extracted from either 
STECK (room temperature) or EDTA (4OC) tubes and that plasma should be extracted within 72 
hours. There appears to be significant variation in miRNA expression; some ‘placental specific’ 
miRNAs could not be detected at all and others are expressed in non-pregnant women. This 
variation may make quantitative comparison between normal and abnormal conditions difficult. 
Further work (using array or sequencing based technologies) is needed to determine whether 
specific miRNA signatures can be ascribed to individual congenital anomalies.    
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1. Introduction  
 
The process of prenatal diagnosis is most developed for chromosomal abnormality. It 
has traditionally involved population based screening to define a high-risk group. These 
women are offered invasive diagnostic testing to confirm the presence of an 
abnormality. Most screening processes are non-invasive, that is they do not place the 
pregnancy at risk. These screening tests commonly involve ultrasound and / or analysis 
of maternal serum proteins. Screening tests do not identify all affected cases and define 
some normal pregnancies as being high risk. In contrast, invasive tests, such as 
amniocentesis and chorionic villus sampling (CVS) are diagnostic, but the process of 
sampling amniotic fluid or placental tissue introduces a risk of fetal loss. Another 
limitation of invasive testing is the time taken to confirm the diagnosis – which may be a 
few weeks. During the last few years other non-invasive tools have been developed and 
introduced into clinical practice. These tests focus on direct identification of genomic 
abnormalities rather than on identification of surrogate ultrasound or surrogate 
markers. These tests are becoming more accessible to women and are being more 
widely used in clinical practice. 
 
In 1997, Lo et al. demonstrated the presence of cell free fetal DNA (cffDNA) in maternal 
serum and plasma (Lo et al. 1997). This discovery provided the means for analysis of 
fetal genomic markers purely by collecting a maternal blood sample – effectively a non-
invasive test that did not place the pregnancy at risk of miscarriage (Devaney et al. 
2011; Lo et al. 1997; Legler et al. 2009). Further studies also demonstrated the presence 
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of fetal mRNA in the circulating plasma of pregnant women and this has also been 
shown to be potentially useful for the detection of fetal aneuploidies from maternal 
plasma (Ng et al. 2003; Ng et al. 2004). At present the commonest clinical application of 
this technology is screening for chromosomal abnormalities. There is, however, huge 
potential to evaluate other structural anomalies and placental function through 
investigation of cell free fetal nucleic acids circulating in maternal plasma. 
 
Most recently, studies have shown that fetal microRNAs (miRNA) can also be detected in 
maternal plasma and can be used as molecular markers. An increase in some placental 
miRNAs in maternal plasma has been described in pregnancies affected by  fetal growth 
restriction (FGR) (Mouillet et al. 2010) and there are differences in the expression of cell 
free fetal miRNA (cffmiRNA) in pregnant women with fetuses with neural tube defects 
(NTD) (Gu et al. 2012). The detection and quantification of these nucleic acids could play 
an important role as biomarkers for fetal abnormalities and placental function. 
 
The main motivation for this project is to develop the first steps in the identification of 
cffmiRNA in maternal circulation that can provide us with more information about the 
state of the fetus. In the future, this knowledge would help us to make more informed 
decisions about the course of a pregnancy. We propose to identify differences in the 
expression of cffmiRNA in maternal plasma between normal pregnancies and a range of 
fetal abnormalities. We will study six known miRNAs that are associated with the 
placenta and will compare their expression in fetuses affected by trisomy 21, congenital 
heart defects (CHD) and NTD. We have also compared three different types of collection 
tubes to identify the best way of collecting and transporting samples for extraction of 
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small non-coding RNAs. This methodological optimization will help us in the 
identification of specific miRNAs to detect different abnormalities. 
1.1. Prenatal testing 
Most pregnant women undergo a number of different tests in early pregnancy which 
allow medical practitioners to define risks of common fetal abnormalities. These tests 
fall into two groups - screening and diagnostic tests, which help in the identification of 
congenital abnormalities and birth defects (aneuploidies, structural abnormalities and 
single gene disorders) (Latendresse & Deneris 2015; Jordan et al. 2013). These 
screening tests are typically offered to all pregnant women to identify a group of high-
risk pregnancies. Diagnostic tests are then offered to the high risk group – limiting the 
risk of miscarriage from an invasive test to those that are considered to have a higher 
probability of being affected by the condition (Latendresse & Deneris 2015). Depending 
on these results women can consider their options and make informed decisions.  
 
The time line for screening for chromosomal abnormalities is shown in Table 1-1. The 
Royal Australian and New Zealand College of Obstetricians and Gynaecologists 
(RANZCOG) have published guidelines describing appropriate pathways for screening 
and diagnostic testing (RANZCOG 2015). Most women in Australia are offered combined 
first trimester screening – a test that uses both ultrasound and biochemical markers – at 
11-13+6 weeks gestation (Snijders et al. 1998). Women who attend at a later stage are 
offered second trimester biochemical screening (between 14 and 20 weeks gestation) 
(Wald et al. 1988; Wald et al. 1999). Some women, deemed to be at high risk on the basis 
of family or obstetric history, may be offered a diagnostic test without initial screening. 
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Most screening tools define women as either being at high or at low risk – and the high 
risk cohort are subsequently offered invasive testing ( Table 1-1).  
 
Table 1-1. Options for prenatal screening and diagnosis. 
  Test 
Gestation 
age (weeks) 
Measurements  Detection   
First trimester        
 
First trimester screening  
Combined 
first 
trimester 
screening 
(CFTS) 
Maternal age is take into account a priori to calculate the risk   
Ultrasound 
11+0-13+6 
Crown Rump Length (CRL) Defines viability, number of 
fetuses present and dates 
pregnancy.  Aneuploidy and 
congenital abnormalities 
Nuchal translucency (NT) 
Maternal serum 
Pregnancy-associated 
plasma protein A (PAPP-A)  
Aneuploidy. Serum markers 
may also be deranged in 
pregnancies that develop pre-
eclampsia and IUGR 
  
free B Human chorionic 
gonadotropin (free B hCG)  
  
 
cfDNA screening From 10  
cfDNA screening using 
maternal plasma 
Aneuploidy  
 
First trimester diagnostics  
 
CVS 11-13 
 
Aneuploidy and genetic 
mutations 
 
Amniocentesis >15   
Aneuploidies, NTD and genetic 
mutations  
     
Second trimester 
 
Second trimester screening  
Quadruple 
test 
Maternal age is take into acount a priori to calculate the risk 
Maternal serum  
15-20 
alphafetoprotein (AFP)  
Aneuploidy and congenital 
abnormalities 
  BhCG  
 
  unconjugated estriol (uE3)  
 
  dimeric inhibin-A    
 
Second trimester 
scan 
18-22 
Each chromosomal pattern 
has different syndromes that 
can be detected  
Structural abnormalities  
Markers of aneuploidy 
          
(Wald et al. 1988; Wald et al. 1999; Snijders et al. 1998; RANZCOG 2015) 
 
Combined first trimester screening involves measurement of the ultrasound marker 
nuchal translucency thickness and the biochemical markers free BhCG and PaPP-A. 
Nuchal translucency and free BhCG are both typically increased in pregnancies affected 
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by Down syndrome. PaPP-A is typically decreased(Scott et al. 2009; Jaques et al. 2006). 
The risk for aneuploidy is computed by determining the background risk (based on 
maternal age, the gestational age of the pregnancy and a previous history of trisomic 
pregnancy) and then multiplying this by likelihood ratios derived through comparison 
of the absolute value of the measurement of these markers to known normal ranges 
(Snijders et al. 1998; Snijders & Nicolaides 1994; Royston & Wright 1998; Kagan et al. 
2008). Some groups, such as the Fetal Medicine Foundation, have introduced other 
ultrasound markers, such as recognition of a hypoplastic (absent) nasal bone and / or 
reversed flow in the ductus venosus. These markers have been shown to increase the 
sensitivity and specificity of screening (Cicero et al. 2006; Maiz et al. 2012) These 
ultrasound and biochemical markers are also altered in trisomies 18 and 13 and in 
Turner syndrome – and can therefore be used to define risks for these chromosomal 
abnormalities in addition to trisomy 21.  
 
Second trimester maternal serum screening involves measurement of AFP, hCG and 
oestriol (Wald – as above). This test is known as the triple test. Screening efficacy can be 
further improved by adding a fourth marker, Inhibin A (Wald et al. 1999). A triple or 
quadruple test can be offered from 14–20 weeks gestation and these tests have 
sensitivities of 65% and 75% for a fixed 5% false positive rate. The triple test typically 
gives risk results for trisomies 21 and 18 but not 13. The AFP is reduced in trisomic 
pregnancies, but will be raised in pregnancies that have a neural tube defect (Cuckle et 
al. 1987; Wald et al. 1988; Wald et al. 1977). Some algorithms also give risks for genetic 
conditions such as Smith Lemli Opitz or steroid sulfatase deficiency on the basis of a low 
oestriol (Schoen et al. 2003).  
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Both first and second trimester screening programs calculate risks for aneuploidy by 
taking the background (a priori) risk and adjusting this according to the markers that 
have been measured. If the risk is above a certain level (1 in 300 for combined first 
trimester screening) then the pregnancy is defined as being at high-risk for aneuploidy 
and an invasive diagnostic test is offered. 
1.1.1. Invasive Prenatal diagnosis 
Diagnostic molecular and cytogenetic tests require a sample of fetal or placental 
material. This can only be obtained by introducing a needle into the uterine cavity to 
‘capture’ the sample. One of these tests, often considered to be the gold-standard, is 
amniocentesis. This test involves insertion of a very thin needle into the maternal 
abdomen and uterus under ultrasound control. Amniotic fluid that surrounds the fetus is 
collected and sent to the laboratory for analysis. The test is usually performed from 15 
weeks’ gestation (Shulman & Elias 1993). Fetal cells can either be isolated directly from 
the amniotic fluid, or the fluid can be cultured prior to analysis. (Shulman & Elias 1993; 
Norwitz & Levy 2013). The cellular content includes epithelial tissues that are in contact 
with the amniotic fluid (skin, bladder, lung, gastrointestinal tract). Cytogenetic analysis 
of this material therefore provides a sample that is considered to be very representative 
of the fetus. The sample can be contaminated with maternal cells – and the laboratory 
takes steps to identify this risk before issuing a result. The amniotic fluid sample can be 
analysed directly by, karyotyping, fluorescent in situ hybridisation (FISH), chromosomal 
microarray analysis or qfPCR to give rapid results (RANZCOG 2015). This result is 
normally restricted to chromosomal groups that commonly develop aneuploidy (21, 18, 
13, X and Y). The remaining part of the sample is cultured and the karyotype is 
traditionally reported by staining and cytogenetic analysis but more recently this may 
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involve a molecular (comparative genomic hybridisation) technique. There is a 0.5-1% 
chance of finding mosaicism that may require further testing. A recent meta-analysis 
suggests that amniocentesis has a ≈1:900 risk of miscarriage (if is performed by a 
experience operator), although earlier RCTs suggested this was closer to 0.5%-1.0%,  
which is why amniocentesis is only recommended for high-risk pregnancies (Akolekar 
et al. 2015; Alfirevic et al. 2003; RANZCOG 2015) 
 
Another invasive method of testing is chorionic villus sampling (CVS). This test is 
typically performed at earlier gestations - from 11 weeks gestation (Norwitz & Levy 
2013; RANZCOG 2015) and is consequently the test of choice after early, combined first 
trimester screening. The sample for this test is taken from the chronic villus (the 
developing placenta). This sample of tissue can be aspirated with a needle or a catheter 
and is collected through either an abdominal or vaginal approach respectively. In the 
cytogenetic lab the sample is first dissected and cleaned (to avoid maternal cell 
contamination) to isolate the chorionic villi (Shulman & Elias 1993; Alfirevic et al. 2003). 
A ‘direct prep’ can be used for karyotyping, fluorescent in situ hybridisation (FISH), 
chromosomal microarray analysis or qfPCR and this is then followed by a culture used 
to confirm the initial findings and to examine all chromosomes rather than just 21, 18, 
13, X and Y. Like amniocentesis, CVS can cause miscarriage – and there is approximately 
the same level of risk of fetal loss (Towner et al. 2007; Carter 1976). CVS has the 
advantage that it is performed earlier – potentially providing an earlier test result for 
decision making about termination of pregnancy or earlier reassurance in the event of a 
normal result. The prevalence of placental mosaicism is higher in CVS samples (1-2% 
rather than 0.5-1.0% for amniocentesis) – this can lead to more dilemmas about ongoing 
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management and the need for further testing (Akolekar et al. 2015; Schrijver et al. 
2007). 
 
A third method of sampling the feto-placental unit is cordocentesis (fetal blood 
sampling). This sample is taken by aspiration from the umbilical cord using a thin needle 
under ultrasound guidance. This can only be performed once the umbilical vein is of 
sufficient diameter to allow access – and is therefore typically reserved for karyotyping 
at later stages of pregnancy - after 20 weeks gestation (Tongsong et al. 2000). In this test 
there is no need for culture so results are available rapidly. This was a major advantage 
before the development of FISH and qfPCR as an amniocentesis performed at 20 weeks 
gestation would take 2-3 weeks to culture before a result was available. Because the test 
is also evaluating a different cell line (fetal lymphocytes) it may also, be useful if an 
amniocentesis has demonstrated a risk of mosaicism. On the other hand, the risk of fetal 
loss is slightly higher than for the other diagnostic tests (2%) (Tongsong et al. 2001). 
 
Many laboratories have recently moved away from cytogenetic testing to use a 
molecular based approach. Similar molecular tools are used for all sample types, and 
include quantitative fluorescent PCR (QF-PCR), that is the quantification of specific DNA 
sequence (short tandem repeats, STR) with fluorescent primers (Atef et al. 2011; 
Badenas et al. 2010) and array comparative genomic hybridization (aCGH) which can 
detect unbalanced structural and numerical chromosomal abnormalities (Van den 
Veyver et al. 2009; Filges et al. 2012). The resolution of an array is approximately a 
hundred times higher than that of traditional cytogenetic analysis. The use of arrays has 
therefore led to identification of a number of pathological deletions / duplications that 
could not previously be seen through prenatal testing. The technology has also identified 
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a number of genomic variants that have not previously been recognized and are of 
unknown significance – that can make counseling difficult. The additional information 
available through aCGH typing may present an ethical dilemma as to whether this extra 
information should be reported or not and as to whether this information is relevant to 
the fetus.  
 
All invasive tests introduce a risk of fetus loss, and most of them take more than a week 
to provide comprehensive results. With the isolation of fetal cells from maternal blood 
(Ross et al. 2000) and with the discovery of cell-free fetal DNA (Lo et al. 1997) in 
maternal circulation there have been advances in non-invasive prenatal screening and 
diagnosis that potentially present no risk to the fetus or the mother. 
1.1.2. Non-invasive prenatal diagnostic (NIPT) 
In 1997, Lo et al. demonstrated the presence of cell free fetal DNA (cffDNA) in maternal 
serum (Lo et al. 1997). During pregnancy, in the intervillous space of the placenta, 
maternal blood is in continuous contact with the trophoblast. This allows the exchange 
of oxygen and nutrients between the mother and the fetus. The placenta remodels 
continuously through apoptosis and cellular debris is released into the maternal 
circulation. This is  recognized as cffDNA (Tjoa et al. 2006). The half life of cffDNA 
appears to be very short – so that no fetal load is detectable within two hours of the 
mother’s placenta being delivered (Lo et al. 1999; Rijnders et al. 2004; Smid et al. 2003). 
Maternal plasma contains fragments of both maternal and fetal DNA. Approximately 
10% of the cell free DNA load is fetal rather than maternal in origin – a significantly 
higher load than is seen when looking for fetal cells in the maternal circulation (Chiu et 
al. 2011; Simpson & Elias 1993). The relative concentration of cffDNA increases with 
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gestational age and is also affected by maternal weight, fetal (and placental) number, 
placental volume, and aneuploidies (Rava et al. 2014; Everett & Chitty 2015; Ashoor et 
al. 2012; Lo et al. 1998; Wang et al. 2013; del Mar Gil et al. 2014).  
 
Circulating cell-free fetal DNA is considered to provide a valuable means of identifying 
genomic anomalies in the fetus. Tests have been developed that identify the presence of 
fetal genes not present in the mother (Rhesus D), the presence of genetic mutations that 
are paternally inherited (both X linked and autosomal) (Amicucci et al. 2000; Meaney & 
Norbury 2009; Saito et al. 2000) and cell free DNA testing is essentially diagnostic in 
these circumstances. Cell free DNA can also be examined to identify fetal aneuploidy – 
but should be considered as a highly sensitive and specific screening tool rather than a 
diagnostic tool. Other studies have suggested that there is an increase in the amount of 
cffDNA in the maternal circulation in pregnancies impacted by placental pathologies – 
including complications like pre-eclampsia (Leung et al. 2001; Lo et al. 1996) and 
placenta praevia (Sekizawa et al. 2002). An association between increased cffDNA in the 
maternal plasma and parturition (Phimister & Phillippe 2014) has also being 
hypothesized: When a pregnancy gets to term and the placenta is mature there is a 
greater release of cffDNA that activate leukocytes and macrophages that lead to 
parturition. 
 
Identifying and quantifying very small amounts of cffDNA is a challenging process. There 
are now a number of technologies available. One example, next generation sequencing 
(NGS) counts millions of fragments of DNA and relatively small differences in the 
amounts of cffDNA can be identified in cases where there is fetal trisomy or monosomy. 
With this approach the whole genome found in the maternal plasma is sequenced (i.e. 
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both maternal and fetal cell free components), then the sequences are aligned with the 
known genome and those that correspond to the chromosome being studied are 
counted and compared to reference chromosomes. Techniques like multi-parallel 
sequencing (MPS), has shown sensitivity and specificities close to 100% in almost all 
studies that have examined cases affected by trisomy 21, (Webb et al. 2012; Fan et al. 
2008; Palomaki et al. 2012; Dan et al. 2012) but the sensitivity and specificity is 
reported to be lower for trisomy’s 18 and 13 (Table 1-2) (Bianchi et al. 2012; Liang et al. 
2013; Chiu et al. 2011; Gil et al. 2015). These chromosomes have lower mean levels of 
guanine and cytosine (GC) content compared to chromosome 21 (Chen et al. 2011), 
which makes the recognition of the fragments of these chromosomes less accurate. 
Using a GC adjustment improves the detection of these two chromosomes (Palomaki et 
al. 2012; Jiang et al. 2012). Also, fetal fraction in the maternal circulation tends to be 
lower in trisomy 18 compared to trisomy 21 and euploid cases – so it is harder to 
differentiate between normal and trisomic cases (Ashoor et al. 2012). Finally, trisomy 13 
and 18 pregnancies frequently have mosaic placentas – with a normal cell line included 
in placentation that potentially masks the presence of trisomy (Schuring-Blom et al. 
2002). Targeted MPS uses similar principles - but is focused on sequencing specific 
chromosomal fragments instead of the whole genome. Similar levels of sensitivity and 
specificity seem to be reported using this technology – which has the potential 
advantage that it requires less sequencing time and so more samples can be run 
consecutively, reducing overall costs.  
 
Next generation sequencing can also be used for the detection of sex chromosome 
aneuploidies. A 91.5% detection rate for monosomy X (45X) was reported in one series 
of 45 cases (Nicolaides et al. 2014). The specificity of detection of sex chromosome 
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aneuploidy is however poorer. This may in part be due to the presence of low level 
mosaicism in some phenotypically normal women but also because confined placental 
mosaicism involving sex chromosomes is relatively common (Bianchi et al. 2015).  
 
Table 1-2. Studies of NIPT of trisomy’s 21, 18 and 13 for MPS and Target MPS. 
Authors Technique Aneuploidie Sensitivity(%) 
Specificity 
(%) 
Bianchi et al.  MPS  T21: 89 100 100 
   T18: 36 97.2 100 
   T13: 14 78.6 100 
Liang et al. MPS  T21: 40 100 100 
   T18: 14 100 100 
    T13: 4 100 99.75 
Nicolaides et al.  Target MPS T21: 25 100 100 
   T18: 3 100 100 
   T13: 1 100 100 
Ashoor et al. Target MPS T21: 50 100 100 
    T18: 50 98 100 
 
Measurement of cffDNA in maternal serum can be used as an alternative to the invasive 
tests for high-risk women (following traditional forms of aneuploidy screening) 
(RANZCOG 2015) – but application in this way fails to take advantage of the high 
sensitivity of NIPT test and also restricts the range of aneuploidy that will be detected to 
common trisomies and sex-linked disorders – the test is essentially similar to the rapid 
qfPCR component of a CVS rather than the full karyotype.   
 
A variety of monogenic diseases that show autosomal dominant, recessive or X-linked 
inheritance have also been diagnosed by examination of cffDNA. Examples include 
testing for Huntington´s disease, myotonic dystrophy, early onset primary dystonia,  
haemophilia, Duchene muscular dystrophy and achondroplasia. The investigational 
tools used to detect these conditions are often less compliex than next generation 
sequencing and include  conventional PCR (Amicucci et al. 2000; Meaney & Norbury 
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2009; Saito et al. 2000), quantitative florescent PCR (QF-PCR) (M. C. Gonzalez-Gonzalez 
et al. 2003) or RT-PCR (M.C. Gonzalez-Gonzalez et al. 2003). Detecting paternally 
inherited loci is more straight forward as these will not be present in maternal plasma 
unless the fetus has this variant. Lo and collaborators (1997) used the presence of the 
SRY gene to demonstrate the presence of cffDNA in their original work. Several groups 
have now shown that this loci can be detected with accuracy as early as  the 5th week of 
gestation (Devaney et al. 2011; Lo et al. 1997).  
 
Monogenic testing is also used to define fetal RHD genotype – and this has the potential 
to reduce the need for antenatal immuno-prophylaxis in RhD negative women and to 
alter the surveillance of women potentially at risk of alloimmune disease (Legler et al. 
2009). A number of techniques for RHD genotyping have been reported including  mass 
spectrophotometry, gel or capillary  electrophoresis, but the most common technique is 
real-time PCR - which appears to be the most sensitive and specific of these (Dovč-
Drnovšek et al. 2013; Grill et al. 2009; Al-Yatama et al. 2007; Kimura et al. 2008). 
1.1.3. NIPT and Models of care 
In addition to using NIPT as an investigational tool following recognition of a high risk of 
aneuploidy, two other models for clinical application of NIPT for aneuploidy screening 
have been suggested. The first would be to offer all women NIPT as a primary screening 
test for Down syndrome. As NIPT has been shown to be the most sensitive and specific 
means of screening for common trisomies (Norton et al. 2015; Bianchi et al. 2014) this 
would appear to be a very sensible long term goal. The issue with this in the short term 
is that the test is expensive and if this is included in the health care budget by exclusion 
of another test, say the 12 week scan, then other anomalies excepting the common 
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trisomies may be missed. An alternative strategy that has received much interest is one 
that is described as contingent screening. In this model of care, women continue to have 
combined first trimester screening as the standard of care in screening for Down 
syndrome and other common forms of aneuploidy. If they are very high risk (> 1 in 50) 
then invasive testing (CVS) is recommended – allowing other atypical chromosomal 
abnormalities that would be missed with NIPT to be detected. If the risk is very low (<1 
in 1000) then these women would be reassured that no further testing is necessary. The 
intermediate risk group (1 in 50 to 1 in 1000) would be offered NIPT as a second level of 
screening – providing further reassurance in most cases but identifying some 
aneuploidy cases that would have been missed using a 1 in 50 cut-off for invasive testing 
(Hui & Hyett 2013). Contingent screening takes advantage of the higher level of 
sensitivity that NIPT offers, but restricts its application to 10-20% of women that have 
an intermediate level of risk – making it more cost effective. The model also restricts 
invasive testing to a far smaller number of women – so is an effective means of reducing 
the false positive rate – and the risk of procedural related miscarriage. 
1.1.3.1. Other cell free fetal nucleic acid products 
Other nucleic acids that are derived from the fetal / placental compartment can also be 
isolated from maternal plasma. Placental specific fragments of messenger RNA (mRNA) 
were first identified by Ng and collaborators (2003). mRNA is known to be rapidly 
degraded and the researchers’ were surprised to find the product appeared to be 
relatively stable within maternal plasma. It has been suggested that this is because the 
degraded parts of trophoblast are protected by particles (Ng et al. 2002; Gupta et al. 
2004) known as microvesicles (Tsui et al. 2014) or apoptotic bodies (Ng et al. 2003). 
Studies have shown that mRNA is rapidly cleared after delivery – in the same way as 
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cffDNA – this means that investigators can be confident that any product identified 
during a pregnancy is specifically related to that event (Ng et al. 2003). mRNA could 
potentially be used in the investigation and surveillance of a number of non-genetic 
obstetric complications such as for the detection of preeclampsia and fetal growth 
restriction (Farina et al. 2010; Mouillet et al. 2010; Takenaka et al. 2014). Researchers 
who are interested in predicting / defining pre-eclampsia have examined the role of 
cffmRNAs such as fms-related tyrosine kinase 1 (FLT1), endoglin, placental growth 
factor (PlGF), transforming growth factor–β1 (TGFβ1), and placental protein 13 (PP13) 
(Farina et al. 2010).  
 
Lo et. al also demonstrated the potential value of quantifying cffmRNA for the prediction 
of fetal aneuploidy – although cffDNA is being used as the clinical tool for these 
conditions (Lo et al. 2007). In this work, that focused on cffmRNA they use SNPs directed 
to PLAC4, a gene located in chromosome 21 to identify and quantify expression of this 
mRNA and then showed the presence of trisomy by calculating chromosome dosage 
using the allelic ratio (Lo et al. 2007). Using this cffmRNA biomarker the author’s 
demonstrated 90% sensitivity and 96.5% specificity for trisomy 21. The RNA-SNP 
approach relies on being able to recognize polymorphisms and detection is only possible 
in heterozygous fetuses; in this study it could only be applies in 40% of pregnancies (Lo 
et al. 2007) meaning a broader range of markers (with more SNPs) would be needed to 
make this practical for clinical use. Other potential advantages of using cffmRNA in 
prenatal diagnosis include the fact that these biomarkers are gender and polymorphism 
independent, and that as they are transcribed from genes that are active in the placenta 
there are multiple copies – and therefore potentially higher concentrations of product. A 
big disadvantage of this technique is that it is limited by the variation in the 
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heterozygosity rate, and due to the high number of homozygotes it wouldn´t be useful 
for the whole population. 
 
The demonstration of the presence of fetal nucleic acids in maternal plasma 20 years 
ago has allowed the development of a range of screening and diagnostic tests which are 
now being applied clinically  (RANZCOG 2015). It is likely that there will further major 
technical developments and that the application of molecular genomic techniques in 
reproductive medicine will continue to expand. One novel area of research involves 
identification and quantification of cell free  miRNAs (Keck-Wherley et al. 2011). Fetal 
miRNAs have been recognized in the maternal circulation and have the potential to 
provide more information about the aetiology of some anomalies. 
1.2. miRNA 
One of the most studied RNAs in the past few decades is miRNA, an endogenous nucleic 
acid that is a small non-coding RNA molecule, which is involved in the regulation of gene 
expression and plays an important role in the cleavage or translational repression of 
mRNA. 
 
There are multiple types of small RNAs that are divided into groups by their length and 
by the interaction that they have with the different Argonaute (AGO) family proteins. 
They are classified into three classes in animals: miRNA, small interfering RNA (siRNA) 
and PIWI-interacting RNA (piRNA) (Ha & Kim 2014). These small RNA have similar 
functions but different mechanisms of action, and of these non-coding RNA, miRNA is 
the most highly expressed in somatic tissues (Ha & Kim 2014). 
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These RNA molecules are between 18 and 22 nucleotides in length, and they have been 
reported to have an important roll in developmental timing, differentiation, 
proliferation, cell death and metabolism (Gangaraju & Lin 2009).  They were first 
described in 1993 by Lee et.al and Wightman et.al who detected lin-4 (a gene known to 
regulate the timing of larva development in C. elegans) (Lee et al. 1993; Wightman et al. 
1993). Lee et.al also found that the action of this non-coding RNA was to bind to the 3` 
untranslated region (3`UTR) of the mRNA of lin-14, and as a consequence of this they 
observed a decrease in the amount of LIN-14 protein but not a change in the amount of 
mRNA of lin-14 (Wightman et al. 1993). 
 
Afer this discovery, research focused on undestanding the function of these molecules. 
One of these studies showed that the target recognition of miRNA is the “miRNA seed” 
(at the 5` of the miRNA which extends from the second nucleotide to the seventh 
nucleotide). The 3`UTR region appears to be highly conserved and 60% of  human 
protein-coding genes have a conserved region for miRNA binding (Friedman et al. 
2009). From the moment that a miRNA is transcribed until it regulates mRNA the 
molecule undergoes a series of regulated steps. This biogenesis is facilitated by the cell 
involving a number of different proteins and factors (Ha & Kim 2014). 
 
miRNA play a very important role in different biological pathways. They are in charge of 
regulating the expression of proteins and it are consequently involved in the regulation 
of different diseases and anomalies. They also play a role in determination the fate of 
cells including processes of cell proliferation, cell differentiation and cell death. For 
example, some miRNA can accelerate proliferation and prevent apoptosis by regulating 
the pro-apoptotic gene hid (Kloosterman & Plasterk 2006). miRNAs have also been 
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shown to  play an important role in myogenesis and cardiogenesis, they are needed for 
the maintenance and growth of tissue (Sokol & Ambros 2005) and are important for 
brain function (for example miR-134 can control the expression of a protein that 
controls the development of dendritic spines (Schratt et al. 2006)). These non-coding 
molecules have significant potential as diagnostic and therapeutic tools, which is why 
understanding and detecting these molecules is so important. 
1.2.1. miRNA Biogenesis 
miRNA are transcribed by RNA polymerase II or RNA polymerase III (Borchert et al. 
2006), the transcription can go though a canonical pathway first producing primary 
miRNA (pri-miRNA) transcripts. pri-miRNA has a hairpin structure in which the miRNA 
is inserted with a passenger strand that is then removed during the process of 
maturation, it can also encode one or more stem-loops. The maturation of pri-miRNA 
takes place inside the nucleus; it is initiated by the RNase III Drosha and DiGorge critical 
region 8 proteins, these complexes cleave the 5` and 3` arms of the pri-miRNA hairpin 
(Gregory et al. 2004) (Figure 1-1). It cleaves approximately 11 base pairs away from the 
basal junction between the single-stranded RNA and the double stranded RNA, 
converting it into pre-miRNA of 70 to 100 nucleotides in length. In some cases the action 
of factors like p68 and p72 are required by some miRNA for more efficient cleavage 
(Winter et al. 2009). 
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Figure 1-1. Biogenesis of miRNA. Canonical and non-canonical pathways. 
(Figure from Li & Rana 2014) 
 
After the cleavage the pre-miRNA is exported by Exportin-5 with Ran-GTP to the 
cytoplasm where it can continue the maturation process, these proteins are also in 
charge of protecting the pre-miRNA in the nucleus (Figure 1-1), and for a successful 
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binding of the Exportin-5 the pre-miRNA has to have a defined length of the double-
stranded stem (Winter et al. 2009) that is independent of the sequence. 
 
In the cytoplasm, an enzyme called Dicer cleaves pre-miRNA close to the terminal loop 
and creates a 22-nucleotide miRNA duplex (this endonuclease is regulated by its 
product let-7). The RNA duplex is loaded into an AGO protein to form the RNA-induced 
silencing complex (RISC) (Figure 1-1) that is composed of the RNase Dicer, the Tar RNA 
binding protein (TRBP), the protein activator of PKR and Argonaute 2 (AGO2) which 
also helps to mediate the RISC effects on the mRNA targets (Winter et al. 2009). The 
TRBP and the PACT are not vital in the cleavage performed by Dicer but they make 
cleavage easier. The passenger strand is removed from the pre-miRNA by the AGO 
protein, and the complex becomes a mature RISC. When the RISC is mature the 
interaction between the miRNA and its mRNA target is possible. 
 
Once the mature miRNA is in the RISC complex and binds to the target mRNA the 
complex is activated. This complex can act through different mechanisms including 
translational repression, inhibition of translation initiation, inhibition of translation 
post-initiation and induction of mRNA destabilization decay (Ha & Kim 2014) (Figure 
1-2). For the inhibition of translation initiation, the complex (miRISC) acts on the 
eukaryotic translation initiation factor 4F(elF4F), and represses the 40S small ribosomal 
subunit, 60S subunit incorporation and the formation of the 80S ribosomal complex. For 
the inhibition of translation post-initiation, the complex miRISC inhibits the elongation 
of the ribosome so the ribosome drops the mRNA where it is degraded. Finally for the 
induction of mRNA destabilization decay, the binding of the complex miRISC recruits 
enzymes that causes the mRNA to destabilize (Li & Rana 2014). 
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Figure 1-2. Potential mechanisms of miRNAs to repress mRNA. 
a) miRNA can inhibit the initiation of translation by affecting initiation factors. b) They can inhibit the elongation of 
ribosomes making them to drop off the mRNA. c) They can bind to the target mRNA and recruit enzymes that 
destabilize it. All of these mechanisms could end up in mRNA degradation. (Figure from Li & Rana 2014). 
 
An alternative non-canonical pathway involves transcribed genes that are located in the 
introns (Mirtrons), which make pre-miRNAs directly through splicing and debranching. 
These are then they transported by Exportin-5. Some of this type of miRNA present 5`or 
3` single-stranded RNA tails that need to be trimmed before they are processed by Dicer 
or these processes would be suboptimal. 7-methylguanosine (m7G)-capped, pre-miRNA 
can also be directly produced by transcription without the need of Drosha and 
transported to the cytoplasm by Exportin-1 (Ha & Kim 2014). These two non-canonical 
pathways finish by loading pre-miRNA in the AGO2 where they act as mature miRNAs. 
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Although this process occurs inside the cell there are studies that show that these 
molecules can be found in the circulation as well. This makes the detection and 
identification of miRNA much simpler – and potentially suitable for use as a clinical tool. 
1.2.1.1. Cell free miRNA or circulating miRNA 
In tumour biology, several cancers have been found to have variable expression of cell 
free tumor miRNA and  research continues into developing the value of these markers in  
detection and marking progression of these diseases (Pritchard et al. 2012). 
Intracellular miRNA has been found in various extracellular fluids, but the function and 
the origin of cell free miRNA is not clear. What is known is that these molecules are 
transported in microvesicles or exosomes (Cheng et al. 2014), which protect them from 
being degraded and allow them to remain relatively stable. Some studies looking into 
the communication between cells suggest that the transportation of miRNA results in 
expression in the cell that will receive it rather than in the cell that it originated from 
(Mostert et al. 2011). Cell free miRNAs are found in fluids and are being transported 
from one cell to another, meaning that by simulating cell free miRNA transport 
therapeutic uses could be developed. These findings also make miRNA good candidates 
as diagnostic markers. 
1.2.1.2. Detection and measurement of miRNA 
The expression of the initial transcript does not always match the expression of the 
mature miRNAs (van Rooij 2011). For this reason is better to study and determine the 
quantity of mature miRNA, i.e. the mature molecules are the ones that inform that a 
specific miRNA is present, with potential to act on a target mRNA. Some studies detect 
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pre-miRNA, intracellular mature miRNA and circulating miRNA. Most of these molecules 
are quantified using the same techniques, but require different methods for extraction. 
For NIPT measurement of circulating miRNA is required because of the low numbers of 
fetal cells for pre-miRNA or intracellular mature miRNA.  
 
The method used for detection and measurement of miRNA depends on the type of 
investigation and the interest of the investigator. For example if a study focuses on the 
expression profile of miRNAs, this can be achieved by microarray or sequencing. Whilst 
for studies to determine the quantity of specific miRNAs the technics of choice are 
Northern blott, quantitative real time PCR (qRT-PCR) and in-situ hybridization (ISH). 
Northen Blot has the disadvantage of longer time to produce results and lower 
throughput. More recently qRT-PCR has become the method of choice (Zhao & Fernald 
2005). Results determined by microarray or sequencing have to be verified with other 
protocols for specific targets. 
 
 Microarrays 
 
This method is used for the detection of several targets and to detect the presence and 
regulation of those miRNAs. The first step of this method is to extract the miRNA or the 
total RNA from cells, tissue or fluids. It is better to use a kit with reagents that allow the 
enrichment of small RNAs because small RNAs are only 0.01% of total RNAs (Shingara et 
al. 2005). After the isolation the mature miRNA is labeled using T4 RNA ligase to attach 
the fluorophore-labeled nucleotides which are then directly hybridized to the arrays 
which contain the specific probes for those miRNAs and after some washes the miRNAs 
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are detected (van Rooij 2011; Li & Ruan 2009). In the analysis the findings have to be 
normalized and verified by qRT-PCR or Northern Blot. 
 
 Deep Sequencing 
 
Similar to arrays, this technique is used to detect all the miRNA that is present in a 
sample. It uses Next Generation Sequencing, in which all the small RNA molecules in a 
sample are sequenced. In this technique it is possible to measure the absolute 
abundance and with the help of RNA-folding prediction software, the identification of 
miRNA is possible (Winter et al. 2009). Next Generation Sequencing has a big advantage 
over microarrays because the information obtained from this technique is much more 
complete, but the analysis of the result that MPS creates is much more difficult to 
interpret. 
 
 Real time PCR 
 
RT-PCR is used for the detection and quantification of specific miRNA. It is the most 
commonly used method to verify results or detect specific targets. In this method the 
miRNA is extracted and will be converted into cDNA by a reverse transcription reaction. 
This can be done using two different primers, one containing a stem-loop and the second 
with a universal primer (Winter et al. 2009). The specificity and sensitivity of this 
method depends on the specificity of the primers. 
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 Northern Blot 
 
This technique requires a lot of time and large amount of RNA, it allows the visualization 
of pre-miRNA and the expression of miRNA. In this method the extracted miRNA is 
separated by size in an electrophoresis gel and then is transferred to a membrane in 
which it is fixed by UV or heat. The membrane is hybridized with labeled probes and the 
probes that where hybridized to the target miRNA are detected with streptavidin 
(biotin) or anti-digoxigenin, which will be detected by a chemiluminescent reaction 
(Winter et al. 2009). 
 
 In-situ hybridization 
 
This method allows the detection of longer precursors of miRNA but not the mature 
miRNA because of the small size of the later. It can show miRNA that are expressed in a 
specific tissue or a specific cell during early embryonic development until a certain 
stages of pregnancies (Winter et al. 2009). This technique can shed light on the 
particular roles of miRNA in different processes (Nielsen 2012). 
 
These techniques have been implemented in various clinical contexts in the last few 
years. They can be used by a variety of medical specialties to provide a wide range of 
information on different biological processes.  
1.2.2. Clinical application of miRNA  
Due to the capacity of these molecules to regulate different pathways they have been 
being investigated for application in different specialties in Medicine. Because these 
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molecules regulate two-thirds of the human genome they provide a large amount of 
data. Because of the role of miRNA in the regulation of gene expression these molecules 
have the capacity to regulate many pathways and a number of different types of 
diseases. For this reason much effort is being expended to identify miRNAs and their 
role in regulation of disease. The particular focus is where there may be a option for 
therapeutic intervention(Nana-Sinkam & Croce 2013).  
 
miRNA have been widely studied in the regulation of a wide range of cancers. One such 
study by Liu et al. has shown that specific miRNA could redirect basic functions and 
pathways to tumor development and progression (Liu et al. 2008). Another use for 
measurements of miRNA is the identification of biomarkers which could help in the 
early detection of metastases, allowing an earlier therapeutic response (Nana-Sinkam & 
Croce 2013).  For breast cancer there are many studies that have found different 
miRNAs that can be used as biomarkers for the detection of various forms of this 
particular cancer, but the results are not always consistent. Case-control studies have 
found that miR-21 is up regulated in the blood (Wu et al. 2011) and tissue (Wang et al. 
2010) of women with breast cancer (these results were obtain by RT-PCR and by 
sequencing) (Zhao et al. 2010). Another similar study based on sequencing didn´t find 
this change (Leidner et al. 2013). Furthermore, miR-155 is an other example with 
conflicting results. It was found to be up regulated in tissue (Wang et al. 2010) collected 
from breast cancer patients and also in blood (Leidner et al. 2013) and breast cancer cell 
lines (Roth et al. 2010) by qRT-PCR. But this was not proven by another group using a 
sequencing approach (Wu et al. 2011). Why these differences occur is uncertain, but 
may be explained by variation in ethnicity, sampling etc. (Zhao et al. 2010; Yao et al. 
2013).  
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miRNAs have also been used in the studies of lung cancer(Hennessey et al. 2012), as 
markers for leukemia (Tanaka et al. 2009; Schotte et al. 2012) and for recognition of 
head and neck carcinomas (Chang et al. 2008). Other studies have focused on 
cardiovascular disease. As with the research done in cancer, the studies in this field are 
trying to find biomarkers that can help in the detection of disease. Additionally, they are 
searching for direct miRNA-based therapeutics. In this regard of myocardial infarction 
there have been two miRNAs consistently reported that can be used as biomarkers; miR-
499 (Corsten et al. 2010; Adachi et al. 2010) and miR-133a (Corsten et al. 2010; 
Kuwabara et al. 2011). As in the cancer research, these studies found additional miRNA 
that are down or up regulated but without consistency across research groups; 
examples include miR-1 and miR-208b. In cardio vascular diseases one miRNA has been 
used as a therapeutic miRNA (miR-21); this miRNA prevents the further progression of 
fibrosis and heart failure, and has been shown to lead to an improvement in heart 
function in cardiac disease models (Srinivasan et al. 2013). There are more studies in 
cardiac disease including recognition of the important roll of miR-210 and the miR-146a 
family in atherosclerosis (Raitoharju et al. 2011) and the down regulation of miR-29  in 
myocardial fibrosis (van Rooij et al. 2008). 
 
Non-coding RNA molecules have been studied in a lot of other fields of medicine such as 
neurodegenerative disorders, which are focusing the research on the possibility of using 
miRNA as a therapeutic tool. In Parkinson’s diseases the analysis of brain tissue post 
mortem of patients with the disease, compared to those without, reveal differential 
expression of miRNA. miR-133b is normally abundant in the brain but in patients with 
Parkinson’s is less abundant, and this miRNA is found to be involved in dopaminergic 
neuron differentiation (Maciotta et al. 2013). Also, they are being studied in metabolic 
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diseases, and their involvement in the regulation of lipid and glucose metabolism 
(Fernández-Hernando et al. 2013). The therapeutic capacity of these molecules is as yet 
unclear. In some fields there are concerns about using miRNA as therapeutic drugs, 
because one miRNA can regulate more that one target mRNA. Therefore alteration of 
one miRNA can affect many pathways (Gaynullina et al. 2015). For this reason it is better 
to have a full understanding of the different paths that one miRNA regulates so we can 
identify all the possible outcomes. It seems a lot more information is required before 
these molecules can be safely used in a therapeutic setting. 
 
As discussed, miRNAs can affect many mRNAs and has a big impact in the field of 
obstetrics. In particular much research has focused on the involvement of these 
molecules in developmental biology. This research is discussed in the following section.  
1.3. miRNA in Obstetrics 
Detection of cell free fetal DNA in maternal circulation has become a well-established 
method for screening for Down syndrome, other common aneuploidies, fetal rhesus-D 
status and to establish fetal gender (Hyett et al. 2005; Hyland et al. 2009). Research has 
also identified changes in miRNA expression in the serum / plasma of pregnant women 
carrying fetuses affected by different abnormalities as well as in pregnancy with adverse 
outcomes (Sankaran et al. 2011; Tang et al. 2013). Several groups are also attempting to 
describe how certain miRNA supress genes and to identify which gene(s) are being 
supressed. These molecules could potentially be used as an indirect means of detecting 
these congenital abnormalities or pregnancies with adverse outcomes. Studies related to 
miRNA in pregnancy have focused on prenatal diagnosis of aneuploidies, cardiac 
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abnormalities, adverse pregnancy outcomes (pre-eclampsia / IUGR / preterm delivery / 
stillbirth), neural tube defects (NTD) and other abnormalities. 
 
These non-coding molecules have not just been studied in the maternal blood, but also 
within the tissue of fetal or placental origin and also in mouse models (Keck-Wherley et 
al. 2011). As invasive testing is associated with a risk of miscarriage, recent research has 
focused on the identification of cell free nucleic acids, which can be investigated without 
putting the mother or fetus at risk.  
 
A number of placenta specific miRNA have been identified in normal pregnancies (Liang 
et al. 2007; Kotlabova et al. 2011), however no research has been done in relation to 
expression of these placenta specific miRNA in pregnancies where the fetus is affected 
by a congenital anomaly. Further work is needed to determine whether these placental 
specific markers are of value in detecting pregnancies that are affected by fetal 
abnormality.  
 
We have previously discussed how placental trophoblast breaks down, releasing cffDNA 
into the maternal circulation. Placental miRNA is shown schematically in Figure 1-3 
believed to behave in a similar manner. The miRNA is released by the trophoblast and 
transported out of the cell via a number of different pathways including as: - cell 
fragments / microparticles, associated with lipoproteins or RNA-binding proteins 
(AGO2), - apoptotic bodies or microvesicles that are released when the cell is going 
though apoptosis, - nanovesicles (exosomes)(Ouyang et al. 2014) that are derived from 
endosomes and are released from the cell or - from multivesicular bodies, being released 
when they are combined with the cell membrane(Kamhieh-Milz et al. 2014)(Figure 1-3). 
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This provides enormous potential for being able to generate information about gene 
regulation in both the fetus and the placenta. Furthermore, if we can find informative 
markers (like with cffDNA) that identify fetuses affected by structural anomalies this 
would facilitate earlier diagnosis providing pregnant women with an opportunity to 
make informed decisions about their pregnancy.  
 
Figure 1-3. How miRNA is released in to the maternal circulation. 
a) Shows the placenta (the connection between the mother and the fetus). b) Is showing the chorionic villi, which 
allow the transport of nutrients and oxygen form the maternal blood. c) Is showing how the miRNA are transported 
from fetal cells to the circulation of the mother. (Figure from Kamhieh-Milz et al. 2014) 
1.3.1. miRNA expression in Aneuploidy 
The efficacy of cffDNA based non-invasive prenatal testing for common chromosomal 
abnormalities such as trisomy 21 is so high that there is no real clinical need to develop 
a new cell free miRNA based approach. Changes in copy number do, however, alter 
miRNA expression.  
 
One study, based on the segmental trisomy 16 (Ts16Dn) mouse model, a well 
characterized animal model of Down Syndrome identified overexpression of miR-155 
and miR-802 in the hippocampus, and in whole blood, compared to controls(Keck-
Wherley et al. 2011). This study defined differential miRNA expression by miRNA array 
then confirmed these findings with RT-PCR Western Blots. The results contrast with 
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those of Kotlabova et al.(Kotlabova et al. 2013) who found overexpression of miR-155 in 
amniotic fluid derived from DS samples (using RT-PCR). A third study, based on High-
Throughput Quantitative PCR (HT-qPCR), a technique that allows detection of 
differential expression in 1043 human miRNA (Kamhieh-Milz et al. 2014), found four 
miRNA that were under- or over-expressed (miR-27b, miR-483.5p, miR-486.50 and 
miR-888.3p) in trisomy 21 compared to euploid fetuses. The three studies looked at 
different sample types, from different models, using different techniques – so it is not 
surprising that such variable results were described. These studies do, however, confirm 
that there is differential miRNA expression between trisomic samples and controls; 
suggesting that there is potential for these products to be used as potential markers for 
DS – once the biological variability is better defined.  
 
Another interesting example of differential expression of miRNA by microarray involves 
neonates affected by trisomy 13. Individuals affected by trisomy 13 continue to produce 
fetal hemoglobin (HbF) and do not switch to production of adult hemoglobin. This study 
examined miRNAs associated with regulation of HbF (Sankaran et al. 2011). They 
discovered that miR-15a and miR-16-1 play an important role in silencing the fetal and 
embryonic hemoglobin genes. In this study they cultured cells from newborns with 
trisomy13 and found that this miRNA targeted the MYB transcription factor, which plays 
an important role in hematopoiesis. Normal expression of these miRNAs moderates the 
expression of this factor. This is not the case for trisomy 13 where the levels of these 
miRNAs are elevated, which leads to greater down regulation of the MYB transcription 
factor, resulting in the switch of fetal to adult haemoglobin being delayed. One 
consequence of this work is that the research team has developed a better 
understanding of the miRNAs that regulate hematopoiesis. This may in turn help with 
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the development of therapeutic interventions that can be applied in other clinical 
scenarios.  
1.3.2. miRNA expression in adverse pregnancy outcomes  
The main causes of perinatal death are congenital abnormality, preterm delivery – 8.3 % 
incidence in NSW  (3.867 of 25.432 births), placental insufficiency (intrauterine growth 
restriction) - 4.5 % incidence in NSW (1.151 of 25.432 births) and pre-eclampsia - 9.3% 
incidence in NSW (2.374 of 25.432 births) (Li et al. 2010). Stillbirth also continues to be 
a significant problem, affecting 0.9 % of pregnancies (NSW, 222 of 25.432 births). 
Placental pathologies are often implicated in all four of these complications – so 
differential expression of miRNAs involved in placental function may provide a means of 
identifying pregnancies at risk of these adverse outcomes.   
 
Preterm delivery is defined by birth at <37 weeks of pregnancy. Preterm births can be 
sub-divided by gestation and some studies focus on extreme (<28 weeks) or early (28-
34 weeks) cohorts of births. Two studies focusing on understanding and finding 
markers for preterm labor found that miR-388 is expressed in chorioamniotic 
membranes of patients with preterm labor compared to patients at term both without 
labor and in labor, they discovered that this miRNA inhibits the expression of PLA2G4B 
(a phospholipase linked to parturition)(Montenegro et al. 2009). Another study found 
that miR-483-5p has a lower expression in placentas of preterm delivery compared to 
normal term delivery pregnancies (Mayor-Lynn et al. 2011). Both of these studies used 
arrays to find the most significant markers, Montenegro and collaborators use 
computation analysis to find the targets of the miRNAs detected, while Mayor-Lynn and 
collaborators coupled arrays with bioinformatics analysis to identify mRNA and then 
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predict the target genes. There are no data that have been published that demonstrate 
that these miRNA changes can also be determined non-invasively as a cell free fetal 
fraction in maternal plasma.  
 
Pre-eclampsia is a hypertensive disorder, where hypertension is develop after 20 weeks 
gestation in addition to one or more of these condition: proteinuria, maternal organ 
dysfunction and uteroplacental dysfunction (Tranquilli et al. 2014). There are four 
studies reporting differential expression of miRNAs in women with pre-eclampsia. Zhu 
et al recruited 15 women who had severe pre-eclampsia and 8 women with mild pre-
eclampsia (using the diagnostic criteria of the guidelines of the International Society for 
the Study of Hypertension in Pregnancy). They took samples from the placenta at the 
time of delivery and performed a microarray and RT-PCR, which showed 34 miRNA that 
are down-regulated in pre-eclemptic women. They concluded that miRNAs like miR-210 
could be a potential marker, because increases in this miRNA can indicate high degrees 
of hypoxia (poor placentation in pre-eclamtic pregnancies can cause hypoxia). Similarly 
Pineles et al. found an increase miR-210 in 9 women who had pre-eclampsia compared 
to controls. Zhang et al. tested serum samples from 30 women and found up-regulation 
of miR-210 in those –who subsequently developed mild or sever pre-eclampsia. In 
contrast to the study of Zhang et al., Gunet et al. found that miR-152 was down-regulated 
in pre-eclamptic pregnancies but also confirmed that miR-210 is up-regulated. The 
consistent finding that this miRNA was an up-regulated marker in both placental tissues 
and in blood makes it a very good candidate for improving predictive methods for this 
particular disease. 
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 Intrauterine Growth Restriction (IUGR) is traditionally defined as a fetus that has an 
abdominal circumference or estimated fetal weight <10th centile on ultrasound and that 
shows evidence of haemodynamic compromise (for example has absent flow in the 
umbilical artery Doppler) (Lausman et al. 2013).  In a study of 45 pregnancies affected 
by IUGR leading to delivery at a mean of 37.8 weeks of infants weighing mean 2749.3g, 
placental tissue was investigated by next-generation sequencing. The researchers 
demonstrated changes in the expression of seven miRNA, but when they tried to 
demonstrate the same findings in maternal serum they were unable to do so 
(Higashijima et al. 2013). In a second study by Tang et al. miR-141 was found to be up-
regulated in the placenta of IUGR pregnancies. This miRNA is known to suppress PLAG1 
genes, which are implicated in IUGR by regulating the expression of insulin-like growth 
factor 2, which is critical in the early development of the placenta and in fetal growth 
(Tang et al. 2013).  
 
Stillbirth is defined as fetal death in utero at >20 weeks gestation (PSANZ 2009). One 
potential cause is related to poor placentation with defective trophoblast growth or a 
reduce penetration of the trophoblast in the decidua (Hustin et al.). Ventura and 
collaborators studied miR-17 and miR-19b in placentas from women that had early 
pregnancy loss, they showed that these miRNAs were down regulated compared to the 
controls, this study suggest that these miRNAs are involved in the placental invasion 
(Ventura et al. 2013) by the repression of PTEN (a gene involved in the trophoblast  
invasion).  
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1.3.3. Congenital heart defects (CHD) 
In Australia the prevalence of congenital heart defects is 7.8 in 1,000 births in the 
general population and is the cause of approximately 20% of prenatal deaths (Leggat 
2011). There are a large range of malformations, most of which are very difficult to 
detect by traditional methods. (the fetuses don’t show visible signs of the CHDs) (Hunter 
& Simpson 2014). Ultrasound is the most reliable method used to detect CHDs, but this 
technique relies heavily on the experience of the medical practitioner which can lead to 
malformations being missed in the screening process and also cannot identify all types 
of congenital heart defect (He et al. 2013).  Some of the more common CHDs in Australia 
are: transposition of great vessels (103 new cases in 2003), Tetralogy of Fallot (82 new 
cases in 2003) and hypoplastic left heart syndrome (37 new cases in 2003)(Leggat 
2011).  
 
Transposition of great vessels (or arteries) is when the aorta leaves from the right 
ventricle and the pulmonary artery leaves from the left ventricle. (the aorta carries low-
oxygen blood to the body and the pulmonary artery take oxygen-rich blood back to the 
lungs). This CHD can be fixed by a surgery to switch the major arteries (Anon 2013b; 
Anon n.d.). Tetralogy of Fallot causes cyanosis and is characterized by a ventricular 
septal defect (a hole in the part of the septum that separates the ventricles), a 
pulmonary stenosis (thickened and narrowed pulmonary valve), a right ventricular 
hypertrophy (increase in the size of the right ventricle) and an overriding aorta (the 
aorta lies directly over the ventricular septal defect) (Hunter & Simpson 2014). 
Hypoplastic left heart syndrome (HLHS) is when the left side of the heart didn´t develop 
properly, so the body doesn´t receive enough oxygenated blood, it can be fixed by a 
series of surgeries (Hunter & Simpson 2014). 
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Some miRNA are involved in the development of the heart, such as miR-1 and miR-133, 
both of which are involved in the mesoderm differentiation of stem cells and suppress 
endodermal and ectodermal cell fates (Lo et al. 1999). Later in development these 
miRNa also promote and repress cardiomyocyte differentiation (Twiss et al. 2014; Small 
& Olson 2011; Dr. Estefania Lozano-Velasco 2011; Liu & Olson 2010; Thum et al. 2008). 
Other miRNAs are involved in heart disease like miR-29 and miR-21 that can lead to 
fibrosis by repressing extracellular components and stimulating mitogen-activated 
protein kinase that promotes fibrosis (Badenas et al. 2010; Anon 2013b)One recent 
study was done in the tissue of the right ventricle of hearts donated by 15 HLHS patients 
of less than or equal to 13 years of age. Performing an array analysis (confirmed by rt-
PCR) they found 9 down-regulated and 4 up-regulated miRNA compared to the 
control(Sucharov et al. 2015). These miRNA could be useful as marker, but as of yet no 
studies of them have been done in circulation.   
 
Studies made on circulating miRNA for the identification of some heart diseases have 
been performed in adults and they have found some potential markers that can help 
with the identification of the diseases (Voellenkle et al. 2010; Fichtlscherer et al. 2010). 
Fichtisherer and collaborators investigated miRNAs involved in coronary heart diseases 
form eight patients and found four miRNAs that were reduced compared to the controls. 
In comparison Vollenkle and collaborators found three different miRNAs relating to 
chronic heart failure. miRNAs found in adult patients with specific cardiac diseases 
should be investigated in terms of fetuses with cardiac malformations as it could be the 
case that miRNAs involved in these diseases could also be involved in the development 
of congenital heart defects. 
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 One study made by Shasha and collaborators found four miRNA in the serum of 
pregnant women that can be potential markers. They used sequencing of three pooled 
samples of women with fetuses affected by CHD and three controls and the results 
where verified with qRT-PCR. With the validation they found that miR-19b and miR-29c 
are up-regulated in fetuses with ventricular septal defects. miR-375 was also up-
regulated for fetuses presenting arterial septal defects. These three miRNAs, plus miR-
22, were up-regulated in fetuses with Tetralogy of Fallot (Zhu et al. 2013). This study 
makes a very good first approach in the identification of markers for CHD using NIPT, 
however these markers need to be tested in more women carrying fetuses with different 
types of CHD to identify any differences in the expression of these miRNAs This will help 
us to understand if the same miRNA can be regulating different types of CHD or/ and if 
there are specific miRNAs for each type of CHD. In addition looking at miRNAs expressed 
in adults with heart disease may lead us to genes or pathways that can also be affected 
in the development of the heart.  
1.3.4. Neural tube defects (NTD) 
These congenital defects have a prevalence of 10.1 per 10,000 pregnancies in Australia 
(2005)(EA 2008). NTD are birth defects that involve the brain, spine and spinal cord, 
which are originated during the early embryonic development when the neural tube 
doesn´t close completely. In a normal pregnancy the neural tube is developed and closed 
22-24 days after conception. The type of NTD depends on the site at which the neural 
tube failed to close. The most common NTDs are spina bifida (open or closed) and 
anencephaly. Iniencephaly, encephalocele and craniorachischisis are the other, less 
common, types of neural tube defects (Botto et al. 1999).  
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Spina bifida can be one of two main types, open or closed. The defects associated with 
spina bifida are: Meningocele (when the spinal cord extends out of the spine like a sac 
containing nerve fluids, typically this does not lead to nerve damage), Myelomeningocele 
(when the spinal cord extends out of the spine but is not contained in a sac, this can 
cause nerve damage and fluid in the brain), Spina bifida occulta (which has no visible 
signs), Anencephaly (the total or partial absence of the brain and malformed cranial 
vault), Craniorachischisis (a congenital fissure of the skull and spine), Iniencephaly (the 
partial or total absence of cervico-thoracic vertebrae) and Encephalocele (when the 
brain extends out of the skull)(Botto et al. 1999).  
 
During embryonic development there are a large number of miRNAs that play important 
roles in neural tube development. This process is very complex, highly coordinated and 
very regulated. Over the course of neurulation a range of different miRNA that are 
involved can be suppressed or overexpressed at different stages of the development 
(Mukhopadhyay et al. 2011). A mouse model has been used for the detection of the 
miRNAs that are involved in the development of neural pathways. Studies using this 
model have shown that miR-9 is involved in the development of the brain and is 
specifically expressed in the nervous system(Krichevsky 2003). miR-124 and miR-9 play 
an important role in the differentiation of the neural stem cells by regulating the REST 
complex (which silences neuronal genes in non-neuronal cells) (Krichevsky 2003; 
Shenoy & Blelloch 2014). There are a lot of miRNA that help in the development of the 
neural tube, like the let-7 family that helps regulates the cell cycle and differentiation 
(Mukhopadhyay et al. 2011; Maller Schulman et al. 2008). None of these miRNA have 
been identified in maternal circulation. 
  39 
A study made by Gu and collaborators found 6 miRNA in the maternal circulation that 
have a different expression between pregnancies with fetuses with spina bifida 
compared to normal pregnancies (Gu et al. 2012). They performed a miRNA microarray 
in 3 pregnancies with NTDs to detect the differential expression, and then they 
confirmed the finding with qRT-PCR. One of these miRNAs that was up-regulated is miR-
144, which is reported to target PAX3 (a gene required in the closure of the neural 
tube)(Phelan et al. 1997). This study is the first step in the identification of cffmiRNA in 
pregnancies with NTDs, however work still need to be done with a larger cohort of 
patients, so there is better detection of new miRNA, which can allow us to detect this 
abnormality faster and easier.  
 
Current diagnosis of fetuses with congenital abnormalities relies on the ability to define 
the anomaly on ultrasound – which may not occur before the 20 week scan. A non-
invasive prenatal test would potentially allow earlier detection of anomalies by defining 
a group who were high risk and needed a focused scan. Given the fact that potential 
markers (i.e. miRNAs) have been identified for a range of structural anomalies and 
diseases we hypothesize that it will be possible to detect some of these in maternal 
serum.  
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2. Hypothesis and aims of this study 
2.1. Hypothesis 
The developmental processes of fetuses affected by chromosomal abnormality (trisomy 
21) or structural anomalies (cardiac abnormalities and neural tube defects) differ from 
those seen in normal pregnancies. This includes differential expression of miRNAs that 
control developmental genes. We hypothesise that changes that occur in miRNA 
expression are detectable in maternal serum, as cell free miRNA. Further, we propose 
that these changes can be used to distinguish between normal fetuses and those that 
have chromosomal or structural defects. 
2.2. Aims of this study 
To demonstrate that cell free fetal (or placental) miRNAs can be successfully extracted 
from maternal serum and quantified. 
To determine which blood tubes are most suitable for collection of maternal blood, 
maximising our ability to detect and quantify fetal (or placental) specific cell free miRNA 
with a collection system that is robust in clinical practice. This will test effects of storage 
time and temperature. 
To determine whether a series of six placental specific miRNAs are differentially 
expressed in maternal plasma collected from pregnancies affected by chromosomal 
abnormality (trisomy 21) or structural anomalies (cardiac and neural tube defects) in 
comparison to chromosomal and structurally normal pregnancies.   
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3. Methodology 
3.1. Sample collection and processing  
Blood samples were collected from 55 pregnant women attending the RPA Women and 
Babies clinic of Royal Prince Alfred Hospital (RPAH) between April 2014 and June 2015 
Each women signed a consent form approved by the Human Ethics Committee of the 
Royal Prince Alfred Hospital (RPAH) (protocol No X13-0350 & HREC/13/RPAH/484).  
 
Blood samples were collected in three different tubes (EDTA, STRECK or CITRATE). 
Approximately 10ml of whole blood was collected into EDTA and STRECK tubes while 
5ml of whole blood was collected in CITRATE tubes. To enable establishment and 
validation of the methodology the samples were collected from two different groups of 
women. The first group acted as the control group, and blood from these women was 
collected between 12 and 29 weeks’ of gestation. The second group was a small group of 
women whose fetuses had been diagnosed with anomalies. These anomalies included 
Neural Tube Defects (NTD), Congenital Heart Defects (CHD) and Trisomy 21 (T 21). 
Each of these diagnoses was made using non-invasive and invasive tests such as 
ultrasound and serum markers. For the second group the samples were obtained 
between the 11th and 28th week of gestation. Details of the anomalies and of the clinical 
features that were recognised at the time of presentation were obtained from the Fetal 
Medicine Unit medical record. Women were recruited on an opportunistic basis 
dependent on the timing of their presentation to the fetal medicine unit at Royal Prince 
Alfred Hospital. 
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3.2. Experimental design analysis  
To analyse miRNA stability, samples were collected from women with normal 
pregnancies between the 18th and 20th week of gestation. To examine the effect of 
collection tube on miRNA stability the samples were collected into three different types 
of blood tube (i.e. EDTA, STRECK and CITRATE). The experimental plan for the studies is 
shown schematically in Figure 3-1 and Figure 3-2. 
 
For the comparison of conditions (shown schematically in Figure 3-3) we analysed 
blood from 15 pregnancies carrying fetuses with congenital abnormalities, 4 with 
Neural tube defects and 6 affected by different types of CHD.  
 
Each series of studies was performed on samples which were collected and stored at 4°C 
or at room temperature as described in detail below. 
3.2.1. Samples at 4°C  
Prior to aliquoting seven of the control samples were stored for 3 to 6 hours at room 
temperature. After this time the whole blood was aliquoted into tubes of 2 ml for all the 
samples, irrespective of tube type (i.e. approximately 5 aliquots for EDTA and STRECK 
tubes and 2 aliquots for the CITRATE tubes). Two tubes of each tube type were then 
centrifuged at 1950rpm for 20 min and 650μl of plasma was removed and stored at -
80°C. The remaining blood was then placed at 4°C. After 24 and 48 hours the aliquots for 
each tube type were centrifuged and the plasma removed and stored as described 
above. As the number of aliquots was smaller for the CITRATE tubes the effect of 4°C 
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storage was only examined at 3-6 hours as baseline and at 48 hours. This information is 
shown schematically in Figure 3-1. 
 
Figure 3-1. Flow diagram showing the experimental design of the method used in the samples stored at 4°C. 
3.2.2. Samples at room temperature (Rt) 
To investigate the viability of collecting and shipping samples from Vietnam (where the 
fetal medicine group see many more fetal anomalies) the effect of a worst-case scenario 
(i.e. no cold storage and long delivery time) on the measurement of fetal miRNA was 
investigated. 
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Figure 3-2. Flow diagram showing the experimental plan for examination of the effect of storage at Rt and collection 
tube in miRNA expression 
 
In a design similar to that used for the cold storage experiments, control samples were 
collected into each tube type and then held for approximately 24 hours at room 
temperature. The whole blood was then aliquoted (approximately 2 ml/aliquot was 
then centrifuged at room temperature at 1950rpm for 20 min and the plasma (650μl) 
was removed and stored at -80°C. The remaining blood samples were kept Rt, and after 
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  45 
approximately 48 hours one of the EDTA and STERCK were processed as above and 
stored. This process was repeated for the final time point (i.e. 72 hours) for all three 
types of tube (Figure 3-2). 
3.2.3. Samples for the comparison of the effect of fetal abnormality on 
miRNA expression  
These samples were collected and stored at room temperature until processing (4-24 
hours). In total samples were collected from twenty-five pregnancies with diagnosed 
fetal abnormalities (anomalies) and fourteen normal pregnancies (controls). Shown 
schematically Figure 3-3, plasma for extraction of miRNA was obtained as described in 
the previous sections.  
 
Figure 3-3. Flow diagram of the experimental plan for examination of the effect of fetal abnormality presence and 
collection tube type. 
3.3. Description of the miRNAs studied 
The miRNA selected for measurement in this work have been described by Kotlabova 
and collaborators (Kotlabova et al. 2011) as the six most placental specific miRNA. Some 
of these miRNAs were also found by Liang and collaborators to be related to the 
placenta (Liang et al. 2007). The miRNA used were hsa-miR-516-5p, hsa-miR-517*, hsa-
miR-518b, hsa-miR-520a*, hsa-miR-525 and hsa-miR-526b (Table 3-1).  
 
 1 Day  Anomalies 
 EDTA 
STRECK 
CITRATE 
 Spin and store 
at -80 °C 
 Controls 
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To analyze expression, TaqMan® MicroRNA Assays (Life Technologies, Carlsbad, 
California 92008), were used. For this analysis primers were purchased. Each kit is 
supplied with 5X RT primer, a 20X mix of forward and reverse primers, and the miRNA-
specific probes (which were used in the pre-amplification and RT-PCR steps).  
 
Table 3-1. miRNAs studied and their sequences 
Assay Name Mature miRNA Sequence 
hsa-miR-516-5p CAUCUGGAGGUAAGAAGCACUUU 
hsa-miR-517* CCUCUAGAUGGAAGCACUGUCU 
hsa-miR-518b CAAAGCGCUCCCCUUUAGAGGU 
hsa-miR-520a* CUCCAGAGGGAAGUACUUUCU 
hsa-miR-525 CUCCAGAGGGAUGCACUUUCU 
hsa-miR-526b CUCUUGAGGGAAGCACUUUCUGUU 
3.4. 
3.5. Controls used for validation 
In each study a number of different controls were used. Firstly, to control for RT and 
PCR efficiency we used a spike in control. In this study it was the C.elegans miR-39 
miRNA. This was used to assess the validity of the whole protocol and as it is added to 
the tube prior to the RT step. This spike in control has the additional advantage in that it 
has the potential for use as an internal control for the normalization of the data. This 
internal control is necessary as to date there are no well described miRNAs which can be 
used as a normalization control for placental miRNA. In this study the C.elegans miR-39 
miRNA, at a concentration of 1.6x108 copies/μl (2.2μl, Qiagen) was added to all samples 
studied just prior to the reverse-transcription step. As for the other miRNAs, its 
expression in the samples was determined using Taqman probes (TaqMan® MicroRNA 
Assay, cel- miR-39).  
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In addition to the cel-miR-39 (as spike in control), for the analysis of the effect of the 
different fetal anomalies we also included a reference sample in each run. This reference 
sample was made from a pool of miRNA isolated from blood samples obtained from 
women with pregnancies with normal fetuses as well as pregnancies with abnormal 
fetuses. This reference sample was included to enable us to determine the variability 
between runs, for the subset of the miRNAs being investigated. 
3.6. Optimization for the processing of the samples 
The processing and analysis of the samples followed a series of steps (shown 
schematically in Figure 3-4) and described in detail in the following sections. The first of 
these steps was to extract the miRNA from the blood of the pregnant women. Once 
extracted the miRNA concentration was determined using spectroscopic methods. A 
reverse transcription step was then applied to convert the miRNA to cDNA and the 
samples were then pre-amplified, and the miRNAs were quantified using RT-PCR. 
 
Figure 3-4. Flow diagram of the basic processing methodology used in this study 
3.6.1. miRNA extraction 
The extraction of the miRNA from plasma was performed using the Life Technology Kit 
(mirVanaTM ParisTM Kit. Life Technologies, Carlsbad, California 92008) according to the 
manufacturers instructions. This kit uses a series of washes to collect total RNAs. The 
total RNAs are then added to a column and the small RNAs are isolated using an ethanol 
Collection of 
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(section 3.2)  
Extraction of 
miRNA 
(section 3.5.1) 
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of the 
concentration 
(section 3.5.2)  
Reverse 
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(section 3.5.3)  
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(section 3.5.4)  
RT-PCR  
(section 3.5.5)  
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gradient. The extracted small RNAs are then purified further using a second column and 
eluted with nuclease-free water.  
 
In the studies described in this thesis we are examining the expression of fetal miRNA, 
which likely makes up a very small percentage of the total miRNA in the maternal 
circulation. For this reason optimization of the extraction procedure was required. Using 
the methodology described in the Life Technology Extraction kit there are two possible 
places to optimise, the first being the volume of plasma used for the extraction and the 
second being the final step where the volume used to eluted the small RNAs from the 
column could be manipulated. The standard protocol allows extraction of up to 625μl of 
plasma. The first optimization was done using 250μl and 500μl of plasma of two of the 
control samples and measuring the concentration. The second optimization, 
investigated reducing the amount of nuclease-free water from the volume that the 
protocol recommends to elute the small RNA (100μl) to 50 μl.  
 
Based on the results of these optimization steps (described in detail in the results 
section 4.2.1.) all further extractions used 620μl of plasma and 35μl of nuclease free 
water to elute miRNA from the column.   
3.6.2. miRNA concentration assessment 
After isolation the RNA concentration in each sample was analysed using the NanoDrop 
(ND1000 spectrophotometer) and the Qubit (MyQubit miRNA Assay, Qubit® 2.0 
Fluorometer.) assays. The Nanodrop was used to enable measurement of total RNA and 
the Qubit enabled measurement of the quantity of the small RNAs present in the sample.  
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The operation of the NanoDrop is based on two fiber optic cables that have a gap in 
which a minimum of 1μl of sample is loaded. Light emitted by one cable passes through 
the sample and is then ‘detected’ by the other cable. The Purity of the samples is 
measured by calculating the ratio of absorbance at different wave lengths (280, 260 and 
230 nm). This technique measures the concentration of total RNA is by loading 1μl of 
each sample into the sampling arm. 
 
The measurements in the Qubit were done using a kit for miRNA (the Qubit® microRNA 
Assay Kit) this assay is highly selective for quantity but not quality of small RNA, based 
on the quantification of fluorescence in comparison with a reference standard. For this 
procedure the working solution was prepared by mixing the Qubit® microRNA reagent 
(1:200) with Qubit® microRNA buffer Two standards (supplied by the manufacturer) 
were included in each run. For the analysis of samples, the volume required is between 
1 and 20μl and was adjusted to 200μl with the working solution prior to analysis using 
the Qubit® 2.0 Fluorometer  
 
As the Qubit measurement is a more accurate determinate of small RNA concentration it 
was routinely used for standardisation of the small RNA concentration in the samples to 
be analysed. Each sample was analysed at two volumes (2.5μl and 5μl).  
3.6.3. Reverse-transcription (RT)  
Following the measurement of miRNA a reverse-transcription (RT) step was performed. 
The RT step converts the miRNA in to cDNA. This step was performed in two ways, 
depending on whether a pre-amplification step was included in the sample preparation. 
The experimental design for this is shown schematically in Figure 3-5. 
 50 
 
Figure 3-5. Schematic representation of the experimental design using the two reverse transcription protocols. 
 
To measure the sample miRNA levels in the absence of pre-amplification the RT process 
proceeded as follows: a master mix was prepared (Table 3-2. a), and divided based on 
the number of miRNAs being investigated (Figure 3-5). To each portion 5μl of the 
isolated miRNA was added, followed by 3μl of primer specific for the miRNA being 
investigated. The samples were then run in the thermo cycler using the cycling 
parameters described in Table 3-2. b.  
Table 3-2. Reverse-transcription without pre-amplification. 
Shown are a. the contents of the master mix; b. the thermal cycler amplification program 
a. 
  
Per sample(μl) 
100mM dNTPs (with dTTP) 0.15 
MultiScribeTM Reverse Transcriptase, 50 U/μL 1 
10✕ Reverse Transcription Buffer 1.5 
RNase Inhibitor, 20 U/μL 0.19 
Nuclease-free water 4.16 
Total volume 7 
b. 
Step Time (min) Temp ºC 
Hold 30 16 
Hold 30 42 
Hold 5 85 
Hold ∞ 4 
 Sample  RT-Primers  Reverse-
transcription 
(RT) 
 
 
 Isolated miRNA 
 With pre-
amplification 
 
hsa-miR-516-5p 
 
Sample 
 
hsa-miR-517* 
 
hsa-miR-518b 
 
hsa-miR-520a* 
 
hsa-miR-525 
 
hsa-miR-526b 
 
cel- miR-39 
 
Without pre-
amplification  
Primer Pool 
 
Sample 
 
Sample 
 
Sample 
 
Sample 
 
Sample 
 
Sample 
 
Sample 
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In some cases a pre-amplification was performed as follows: the master mix (Table 3-3. 
b) consisted of a primer pool (Table 3-3. a.) (Figure 3-5) which consisted of 5.83µL of 
each 5X miRNA primer being investigated. The isolated miRNA (2ul) was added to 13μl 
of the master-mix/primer-pool and the samples were amplified using the conditions 
described in Table 3-2. b. 
 
Table 3-3. Reverse-transcription step. When performing the pre-amplification. 
a. Reverse-transcription primers pool; b. Content of the master mix 
a. 
 
5X miRNA 
Primers(μl) 
# Of assay 
Total 
pooled 
volume(μl) 
Volume of 
1X TE(μl) 
Total of 
RT(μl) 
5.83 7 40.81 542.19 583.00 
 
  b. 
   
Per Sample(μl) 
RT Primer Pool 6.75 
100mM dNTPs (with dTTP) 0.34 
MultiScribeTM Reverse Transcriptase, 50 U/μL 3.38 
10✕ Reverse Transcription Buffer 1.69 
RNase Inhibitor, 20 U/μL 0.21 
Nuclease-free water 1.14 
Total volume 13.51 
 
3.6.4. Pre-amplification (pre-amp) testing 
Pre-amplification is an optional step between the RT and the real time-PCR. This step 
amplifies the miRNA of interest and is useful in cases where miRNA concentrations are 
low. This step is only performed when following the “with pre-amplification” branch of 
Figure 3-5. The final step of the standard protocol (TaqMan®Pre-amplification, Life 
Technologies, Carlsbad, California 92008) was optimised. 
 
5.83 µL of each 20X miRNA (mix of forward, reverse primers, and the miRNA-specific 
probes) were combined to make the pre-amp pool (Table 3-4. a.). This pool was added a 
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master mix (Table 3-4. b.). 2.5μl of the cDNA was added to 22.5μl of the master mix. 
Subsequently the samples were run in the thermo cycler following the parameters in 
Table 3-4c. 
Table 3-4. Pre-amplification step. 
a. Pre-amp primers pool b. Content of the master mix c. Parameters values to program the thermal cycler 
a. 
20X 
miRNA(μl) 
# Of assay 
Total 
pooled 
volume(μl) 
Volume of 
1X TE(μl) 
Total of 
Pre-
amp(μl) 
5.83 7 40.81 542.19 583.00 
 
  b. 
   
Per 
Sample(μl)  
TaqMan Pre-amp Master Mix (2X) 14.06 
Pre-amp Primer Pool 4.22 
Nuclease-free water 7.03 
Total volume 25.31 
 
 
 
 
c. 
Step Type 
Time 
(min) 
Temp 
ºC 
Hold 10 95 
Hold 2 55 
Hold 2 72 
Cycle (14 
Cycles) 
15 s 95 
4 60 
Hold 10 99.9 
Hold ∞ 4 
 
The final step of the standard protocol is to add 175μl of 0.1X TE buffer (pH 8.0) to each 
sample to give a final volume of 200μl. For the optimization of this step, instead of the 
addition of a 175μl of 0.1X TE buffer, 4 serial dilutions of the pre-amp product were 
prepared (Figure 3-6, 1:8 being the standard dilution). 
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Figure 3-6. Schematic representation of the fold dilution in the pre-amp step. 
3.6.5. Real time Polymerase Chain Reaction (RT-PRC) 
After the RT and pre-amp steps the RT-PCR was performed following the TaqMan® Fast 
Advanced Master Mix protocol (Life Technologies, Carlsbad, California 92008). A master 
mix was prepared as described (Table 3-5) and diluted pre-amp product or RT product 
(3ul) were added to the plate with 7μl of master mix. Subsequently the samples were 
run in LightCycler®480 following the parameters in the Table 3-5. b. The 
LightCycler®480 calculated the threshold cycle value (or crossing point, Ct or Cp).  
Table 3-5. Details of RT-PCR 
a. Content of the master mix; b. thermocycling parameters used to amplify miRNAs of interest on the Roche 
LightCycler®480. 
a. 
  
384- well 
plates (μl) 
   TaqMan® Fast Advanced Master Mix (2✕)  5 
TaqMan® Gene Expression Assay (20✕)  0.5 
Nuclease-free water 1.5 
Total volume 7 
 
      b. 
Step Type 
Time 
(min) 
Temp ºC Cycle 
Hold 2 50 
 Hold 0.2 95 
 Denature 0.03 95 
40 
Anneal/extend 0.3 60 
 Fold dilution 
0.1X TE buffer (pH 8.0)  
 RT product  Pre-amp product 
 
1:1 
 
1:2 
 
1:4 
 
1:8 
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3.7. Data analysis 
The data was analysed by calculating the ΔΔCt values from the Ct values generated by 
the LightCycler®480. This calculation takes into account the Ct-values of each sample, 
the Ct values of the spike in control and the Ct-values of reference sample (Equation 
3-1). In the case of the time and temperature experiments the data obtained from the 
baseline sample (i.e. the earliest time point at 4°C) was used as the reference sample. 
The studies investigating the expression of miRNAs in the fetal anomaly cohort used the 
pooled sample included in each run as the reference sample. 
Equation 3-1. Equation of the ΔΔCt. 
CT.GOI: Ct value of the miRNA of the sample of interest; GM.HK: Ct value of the spike-in of the sample of interest; 
CT.GOI.QC: Ct value of the sample of reference; GM.HK.QC: Ct value of the spike-in of the sample of reference. 
                 )                ))  
.  
The data was analysed using SPSS software version 22.0 (SPSS, Ing, Chicago, USA) and 
the graphics where generated in GraphPad Software (GraphPad Prism version 6.00, La 
Jolla California USA, www.graphpad.com). A t-test was performed for the detection of 
differences in the optimization. A Mann-Whitney U test was used to compare the relative 
expression level of the miRNA in the time and temperature experiment, and for the 
analysis of the effect of fetal anomalies on miRNA expression. 
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4. Results 
4.1. Description of the samples  
A total of 42 blood samples collected from pregnant women were analysed in this study. 
The range of abnormalities and the way they are grouped for this study is described in 
Table 4-1. The characteristics of the sample population, in particular the screening 
criteria for fetal abnormalities, are reported in Table 4-2. The measurements obtained at 
first trimester screening such as crown-rump length (CRL: mm), nuchal translucency 
(NT: mm), free beta human chorionic gonadotrophin (free BhCG: multiple of the median 
(MoM)) and pregnancy associated placental protein A (PAPP-A: MoM) are included. 
Some women did not have first trimester screening – so this information is only 
available for a subgroup of cases.  
 
The different variables for the groups with genetic abnormalities were compared to the 
pregnancies with normal fetuses (controls) (Table 4-2). When the group with congenital 
abnormalities as a whole were compared with those with normal pregnancies there was 
no difference in age or gestational age. There is a significant difference between the 
controls and the neural tube defect group for the CRL and the NT (p<0.01). Furthermore, 
there is a significant difference between the controls and congenital heart defect group 
for the NT (p<0.01).  
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Table 4-1. Congenital abnormalities studied. 
Condition  N Specific Abnormalities 
Congenital abnormalities 
(C-A) 
T21 14 Trisomy 21 
T18 1 Trisomy 18 
Neural Tube Defects (NTD) 
S-B 3 Sacral Spina Bifida  
Anen 1 Anencephaly 
Congenital Heart Defects 
(CHD) 
HLHS 2 Hypoplastic left heart syndrome  
Other 
1 Corrected Transposition of great aeries 
1 Tetratology of Fallot with absent pulmonary syndrome 
1 Ventricular septal defect, overriding aorta 
1 Arch Hypoplasia 
 
Table 4-2. Characteristics of the various patient populations studied. 
  
Controls 
Chromosomal abnormalities (C-A) Neural Tube Defects (NTD) Congenital Heart Defects (CHD) 
 
All C-A T21 T18 All NTD Spina Bifida Anen All CHD HLHS Other 
N 16 15 14 1 4 3 1 6 2 4 
Age 31.4 ± 3.5 37.2 ± 3.8 37.1 ± 4 39 29.5 ± 3.5 28.3 ± 3.2 33 31.2 ± 1.9 31 ± 2.8 31.3 ± 1.9 
Gestational age 
(Week) 
22.8 ± 7.4 13.6 ± 1.9 13.7 ± 1.9 12 17.3 ± 2.9 18.7 ± 0.6 13 20.3 ± 3.9 19.5 ± 0.7 20. 8 ± 4.9 
N+ 11 12 11 1 2 1 1 4 1 3 
Crown-rump length 
(CRL) (mm) 
64 ± 6.3 64.9 ± 9.9 66.2 ± 9.1 50 66.3 ± 2.3* 67.9 64.6 68.0 ± 8.3 77.0 65 ± 7 
Nuchal translucency 
(NT) (mm) 
1.9 ± 0.5 3.2±1.5* 3.3 ± 1.5 2.2 1.4 ± 0.3* 1.6 1.15 2.8 ± 1.8* 2 3.1 ± 2.1 
Free beta hCG. 
(MoM) 
1.6 ± 1 2.7 ± 2.3* 2.9 ±2.4 0.2 1.4 ± 0.1 1.49 1.31 0.9 ± 0.2 0.82 0.9 ± 0.2 
PAPP-A. (MoM) 1.6 ± 1 0.55 ± 0.4* 0.5 ± 0.4 0.32 0.6 ± 0.4 0.8 0.3 1.4 ± 0.7 1.8 1.4 ± 0.7 
Rt:  Experiment at room temperature, 4°C: Experiment at 4°C; N+: total number of samples used for the analysis of the first trimester screening; Anen: Anencephaly; T21: Trisomy 21; 
T18: Trisomy 18; HLHS: Hypoplastic Lefts Heart Syndrome. (Values are shown as mean ± SD).  
* Significantly different from control (p<0.05)
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4.2. Optimization of sample processing 
The characteristics of patient samples used for these optimisation studies are shown in 
Table 4-3. All samples were obtained from women with normal pregnancies. 
Additionally no differences in fetal characteristics at the first trimester screening were 
observed for the samples analysed at after incubation at room temperature or 4 °C. 
Table 4-3. Characteristics of the controls studied. 
  Controls 
 
All controls  Rt  4°C 
N 29 7 7 
Age 31.5 ± 3.6 32 ± 3.8 31.1 ± 4 
Gestational age 
(Week) 
21.3 ± 5.6 19.6 ± 1.0 19.3 ± 0.5 
N+ 23 6 6 
Crown-rump length 
(CRL) (mm) 
64.6 ± 7.2 60.8 ± 7.7 65.5 ± 8.8 
Nuchal translucency 
(NT) (mm) 
1.8 ± 0.4 1.8 ± 0.3 1.6 ± 0.4 
Free beta hCG. 
(MoM) 
1.4 ± 0.8 1.3 ± 0.5 1.4 ± 0.7 
PAPP-A. (MoM) 1.5 ± 1 1.5 ± 1.3 1.3 ± 0.7 
Rt:  Experiment at room temperature, 4°C: Experiment at 4°C; N+: total number of samples used for the analysis of the 
first trimester screening 
4.2.1. miRNA extraction 
For the optimization of the volume of blood to be used for nucleic acid extraction we 
compared 250μl and 500μl of starting material (plasma). These volumes were eluted 
with 100μl of nuclease-free water and the miRNA concentration in the eluent was 
measured using Qubit. We observed (Figure 4-1. a.) that there was little difference in the 
concentration of the eluted miRNA, but there was a difference in miRNA concentration 
between samples.  
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a. 
 
b.   
 
c. 
 
Figure 4-1. Optimization of the extraction step 
a. Difference between the initial amount of plasma added in the extraction; b. Difference in concentration between the 
volume of eluent added (nuclease-free water) at the end of the extraction to elute the miRNA c. difference in amount 
between the volume of eluent added  (nuclease-free water) at the end of the extraction to elute the miRNA. 
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For the second optimization test we used a starting volume of 620μl of plasma and two 
different volumes of nuclease-free water to elute the miRNA. As before, the miRNA 
concentration was measured using the Qubit. The results are expressed as ng/ul and 
total miRNA extracted (Figure 4-1. b. and c. respectively). Again the results were 
variable between the samples with, as expected, a lower concentration of miRNA with 
the addition of more nuclease-free water. There was no difference between tube types 
and in particular for CTR 2 the amount of miRNA eluted was the same irrespective of 
elution volume. (For these two optimization steps no statistical analysis was performed 
as there was only one datum for each variable).  
 
 
4.2.2. miRNA concentration assessment 
To investigate the optimal method to determine the miRNA concentration two different 
techniques were used. The parameters for these tests were: 620μl of starting material 
(plasma), 100μl of eluent (nuclease-free water). Each sample was measured in the 
NanoDrop (1μl of sample) and the Qubit (2.5μl of sample). Irrespective of tube type, and 
not unexpectedly the concentrations of RNA measured by the NanoDrop were much 
higher than the concentration of small or miRNAs determined using the Qubit (Figure 
4-2.  a.). 
 
The effect of volume loaded (i.e. 2.5μl and 5μl) was also examined in the Qubit assay 
system. The parameters for these readings were: 620μl of starting material (plasma), 
samples were eluted with 50μl of nuclease-free water and read using the Qubit. 
Increasing the volume loaded did not increase miRNA concentration and was not 
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affected by tube type (Figure 4-2. b.). (As before no statistical analysis was performed, as 
just one datum was collected for each variable).  
a. 
 
b. 
 
Figure 4-2. Optimization of the measurement step. 
 a. Difference between NanoDrop and Qubit for the measurements of the concentration; b. Difference between the 
miRNA concentrations with different initial amounts of extracted miRNA (2.5μl and 5μl) measured in the Qubit 
4.2.3. miRNA primers and probes  
Initially the cycle threshold (Ct) of cel-miR-39 was used to ensure reverse transcription 
and amplification, dilution curves are shown in Figure 4-3. For cel-miR-39 the Ct-values 
increased linearly, representing a decrease in concentration, with increasing dilution 
(Figure 4-3. a). Dilution curves for the other miRNAs examined were performed to 
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establish the linear range (Figure 4-3. b). Unfortunately, due to low concentrations, miR-
526 and miR-517 failed to amplify before Ct 35 and for this reason were not included in 
any further analysis. The dilution curves for the remaining miRNAs are shown in Figure 
4-3. b. 
a.  
b.  
Figure 4-3. Efficiency of miRNA primers and probes. 
a. Efficiency of primers and probes with out Pre-amp; b. Efficiency and optimization cel-miR-39, with Pre-amp and 
without. 
 
4.2.4. Pre-amplification testing 
To ensure that the pre-amp was working correctly and not interfering with the RT-PCR 
process, and to find the optimum dilution of the pre-amp product, a second set of serial 
dilutions were preformed and the results were compared to those obtained from 
samples which had not undergone the pre-amp step. The linear trend observed in the 
previous section was also observed for the pre-amplified products for all the miRNA in 
the study (Figure 4-4.  a-d).  
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The results also appear to show a difference in the Ct-values between the pre-amp 
samples and the non-pre-amp (p<0.05). In all cases the pre-amp samples amplified at an 
earlier Ct reflecting an increase in miRNA. Additionally for all the miRNAs studied, the 
non-pre-amp has an even later Ct-value (i.e. lower concentration) than the most dilute 
sample. Furthermore as shown the Ct-values for all the miRNAs studied decreased in a 
linear fashion with dilution (Figure 4-4. a-d). 
 
  
         a.                                b.   
 
 
 
 
 
          
 
 
 
 
             c.          d.  
Figure 4-4. Optimization of Pre-amp and efficiency of miRNA primers and probes. 
a. miR-516 with Pre-amp and with-out; b. miR-518 with Pre-amp and with-out; c. miR-520 with Pre-amp and with-
out; d. miR-525 with Pre-amp and with-out.
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4.3. Results of the experiments to test the stability miRNA in each tube in 
different conditions.   
4.3.1. Control samples at 4°C 
The results of the miRNA analysis for the seven control samples kept for 4 hours, 1 day 
(1D) and 2 days (2D) at 4°C are shown in Figure 4-5. Data was only analysed if there 
were more than two time points measured. As shown the Ct values were very variable 
between the samples analysed and across the time points studied. In general due to the 
high variability there was no observable differences between the tubes for each time 
point. However for the STECK tube, the miR-520 at 2 days appeared different to the 
other time points analysed. (Figure 4-5. a). Additionally for the EDTA and STRECK tubes 
there tended to be less variability in Ct at the 4 hours point when compared with the 1D 
or 2D analysis. This pattern was not seen for the CITRATE tubes. 
 
The results were then expressed as the level of expression relative to the internal 
control (Cel-miR-39) and the results are shown in Figure 4-6. As shown the plasma 
concentration of miRNAs were affected differently depending on the duration between 
collection and extraction and the tube type. Interestingly the citrate tube showed the 
least variability between time points and the STRECK tube the greatest. Additionally 
miRNA-520 and miRNA 525 appeared to be more stable than miRNA-516. In these 
experiments the miRNA-518 did not amplify using the parameters described in the 
methods section and was not used for these analyses. 
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a.  EDTA     b.  STRECK    c.  CITRATE 
Figure 4-5. Raw Ct-value. Variability between the 7 control samples, showing the effect of collection tube over three time points at 4°C.  
a. EDTA; b. STECK; c. CITRATE. 
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a. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
b.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6. Relative expression of all the miRNA over time for each tube.  
a. Effect of time; b. Trend of each tube. 
# p<0.05 Significant difference for the tube compared to the first and second time points.   
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4.3.2. Control samples at room temperature (Rt) 
Analysis of the effect of maintaining samples at room temperature for four days is 
shown in Figure 4-7. As before no analysis was performed on samples where there were 
less than two time points.  
 
As previously shown, there was variability in the Ct values obtained for each sample. 
Overall there was no significant difference in the CT value between the tube types for 
each time point. However for the EDTA tubes there was a significant decrease in the 
level of miR-525 between the third and fourth days (p<0.05)  (Figure 4-8. a. miR-525). 
The data were then expressed relative to controls (Cel-miR-39 and first time point). As 
shown (Figure 4-9) there were different trends for each tube type over the 4 days of the 
study. The EDTA tubes appeared to have an increasing relative expression level of miR-
516. The level of miR-520 was increased in the samples collected in EDTA tubes, whilst 
the pattern for miR-525 was different with decreased relative expression at day 4. This 
pattern was less obvious for the STRECK tubes and for the CITRATE tubes Figure 4-7. b. 
 
 It is best to use EDTA or CITRATE tubes if the samples can be stored at 4°C and is better 
to store the plasma at -80°C before the third day. On the other hand if the samples are 
going to be left at room temperature before the plasma is separated it is best to used 
STRECK tube and they shouldn’t be left more than three days.  
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a.   EDTA     b.  STRECK    c.  CITRATE  
  
Figure 4-7. Raw Ct-values. Variability between the 7 control samples, showing the effect of collection tube and time though three time points at Rt.  
a. EDTA; b. STECK; c. CITRATE. 
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Figure 4-8. Relative expression of all the miRNA during time for each tube left at Rt.  
a. Effect of time; b. Trend of each tube. 
# p<0.05 Significant difference for the tube compared to the third time points.
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4.3.3. Samples for the comparison of different fetal anomalies 
In the analysis of different conditions we first compared all the congenital 
anomalies against the controls. For these studies, samples were collected in the 
three different tubes, left at room temperature and the plasma was stored within 
24 hours. On the whole the pattern of expression of each miRNA was similar 
irrespective of the collection tube used. 
 
When the data obtained from the different groups of congenital abnormalities as 
a whole were compared with the controls no major differences in levels of any of 
the miRNAs was observed. There appeared to be a trend toward decreased levels 
of miRNA 525 in the NTD group and the CHD group but due to the small numbers 
this failed to reach significance.  In contrast, when the specific conditions within 
each group were compared to controls, significant differences were observed for 
miR-520 that had a higher level of expression in the HLHS group compared to 
the normal pregnancies (p<0.05) (Figure 4-9, c). 
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Figure 4-9. Relative expression of all the miRNA for the different conditions and for the different specific conditions. 
a. Relative expression for miR-516; b. Relative expression for miR-518. c. Relative expression for miR-520; d. Relative expression for miR-525. 
* p<0.05 Significant difference between the conditions and the non-pregnant women.
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Figure 4-10. Comparison between normal pregnancies and non-pregnant women. 
Normal-P: normal pregnant women; Non-P: non-pregnant women. 
* p<0.05 Significant differences. 
 
 
As some of the miRNA in the study didn´t amplify, we compared the normal pregnancies 
with three non-pregnant women, to see if they are expressed in non-pregnant women. 
For these studies blood was collected only in EDTA tubes. As with the pregnant women 
miR-517 and miR-526 failed to amplify. The circulating miRNA level of miR-525 was 
significantly lower (p<0.05) in non-pregnant women than pregnant women (Figure 
4-10). There was, however, definite evidence of the presence of miR-525 in non-
pregnant women – which contrasts to previous data suggesting this miRNA is placental 
specific.  Similarly, miR-518 and moR-520 appear to be non-specific – and were in fact 
found in similar levels in pregnant and non-pregnant women. In the non-pregnant 
women miR-516, failed to amplify suggesting that this miRNA is indeed fetal in origin. 
miR-516 was therefore the only miRNA that we tested that proved to be both present 
and placental specific.  
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5. Discussion 
5.1. Optimization of sample processing 
In addition to using cell free fetal DNA to screen for chromosomal abnormalities or 
genetic anomalies, it may be possible to use other cell free nucleic acids to screen for 
other functional anomalies of the fetus and placenta. Cell free fetal DNA is the most 
studied cell free nucleic acid to date. Several groups recognised that, in order to be able 
to use this test in clinical circumstances, it was first necessary to define how the 
laboratory process was affected by different sampling and storage conditions. In 
establishing research in cell free fetal miRNAs we therefore felt that it was first 
important to define criteria for sample collection so that this process was appropriately 
controlled in subsequent experiments. 
 
There are two published studies that document the impact of transport conditions / 
sampling tubes on cell free fetal DNA (Barrett et al. 2011; Wong et al. 2013).   These 
studies were performed using blood from pregnant women, collected at 10 to 16 weeks 
of gestation. The blood was collected into either EDTA or cffDNA STRECK tubes. Samples 
were then stored at a range of temperatures and for various time intervals before being 
processed, with nucleic acid extraction from the plasma. These studies showed that the 
concentration of cell free DNA in EDTA tubes increases over time; and consequently the 
relative proportion of fetal to maternal product decreases – thus making subsequent 
analysis more difficult. In comparison, cell free DNA levels were stable in the cell 
stabilizing, STRECK tube for a longer time period. As a consequence, the STRECK tube 
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has become the universal product used for cffDNA analysis performed clinically to 
screen for chromosomal abnormalities. Other groups have, however, described that fetal 
DNA is stable in EDTA tubes for up to nine days (Clausen et al. 2013). In this study, 
whilst the total DNA in the circulation increases over the first four days, it then 
remained stable for a further five days more. These three studies used different 
techniques to process their samples but all authors suggested that cell free fetal DNA 
concentrations would vary depending on the conditions in which the samples were 
stored and transported.  
 
There are no studies describing sample stability of cell free fetal mRNA and / or miRNA. 
Moving away from cffDNA towards miRNA to identify new biomarkers would expand 
the range of abnormalities that can be detected. Placental specific miRNAs have been 
detected (Mouillet et al. 2010), but the change in the expression of these miRNAs with 
respect to different abnormalities has not been extensively studied. To draw any 
conclusions a large number of samples need to be collected and studied. To enable this 
and due to the low prevalence of many of these abnormalities it is likely that the 
samples will need to be collected from a number of clinical sites. For this reason, the 
samples will be coming from a range of locations often some distance from the 
molecular lab. Therefore, before such studies are undertaken, the methodology for 
sample collection, transport, storage and processing needs to be confirmed. To make 
this possible, the first aim of this study was to identify the effect of storage condition and 
collection tube on the expression of fetal miRNAs. In this study we have reported a 
number of experiments used to optimise sampling and lab preparation technique.  
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From a laboratory perspective, the first step in optimisation involved deciding on the 
optimal amount of plasma required to extract sufficient quantities of miRNA for analysis. 
This is particularly important when the miRNA of interest, in this case fetal miRNA, are 
likely to be in low abundance compared to other sources of miRNA (here maternal 
circulating miRNA). In this study a comparison between two different volumes of 
starting plasma showed no overall differences in the quantity of miRNA extracted. We 
used the maximum volume of plasma possible according to the extraction kit 
manufacturers’ instructions; but note that this volume was lower than that reported by  
Gu and collaborators in the detection of cffmiRNA (Gu et al. 2012). It would be expected 
that when the amount of plasma used in an extraction is doubled the amount of small 
RNA collected would also be doubled. This was not observed during the optimization. A 
possible explanation for this result could be that the column became saturated with 
small miRNA and so any additional miRNA were not fully retained. The amount of 
miRNA did increase slightly (1.5 fold) when the starting volume of plasma was increased 
so the maximum possible volume was used.  
Although it was not statistically significant, there did appear to be some variation in the 
Ct and relative expression of miRNAs dependent on the type of tube used for collection. 
We therefore feel that it will be appropriate to standardise tubes across collection 
centres for future work. Although the STRECK tubes are more expensive ($10 each!) 
they do appear to be more robust when samples are transported at room temperature. 
This is similar to some of the findings in relation to cffDNA (Barrett et al. 2011; Wong et 
al. 2013). We do note, however, that this trend was not consistent across miRNA – with 
higher within sample variability in miR-516 than the other miRNAs – and this was the 
only miRNA that proved to be placental specific. Once specific miRNA candidates for 
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prenatal diagnosis have been identified it will be necessary to repeat optimisation 
studies. When the final volume used to elute the small RNA is halved the final 
concentration approximately doubles in most of the cases. Meaning that the smaller the 
volume used to elute, the higher the concentration of small RNA that can be used in the 
rest of the process (the same total quantity of miRNA). The lowest practical amount that 
can be used for the downstream experiments was 35µl and for this reason it was 
established as the standard eluent volume and used for all later experiments.  
To determine the concentration of miRNA the values measured by the Qubit were more 
informative than the NanoDrop. Not unexpectedly the NanoDrop yielded values an order 
of magnitude higher than the Qubit because it measures total RNA. To more accurately 
quantify miRNA the Qubit was used and volumes of 2.5µl- 5µl of the isolated miRNA 
yielded values above the lower detection limit of Qubit, and in a linear fashion.  In this 
study to minimize volume of sample used the quantitation of miRNA concentration was 
typically performed using 2.6µl of undiluted sample. 
 
Six previously described placental specific miRNAs were used for the optimisation 
experiments. These were chosen from the limited amount of literature available that 
describes placental specific miRNAs. Liang et. al examined 40 different human tissues 
with the objective of defining specific miRNAs for each (Liang et al. 2007). Within the 
tissue bank they used was one placental sample. They tested a range of miRNAs, using 
qRT-PCR – although it’s not clear how these were selected. Fifty-six miRNA’s appeared 
to be placental specific including miR-526b.  
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Kotlabova et al. (2011) examined plasma samples from 23 pregnant and 10 non-
pregnant women with an aim of defining placental specific cell free miRNAs in maternal 
circulation. The plasma samples were collected at 12, 16 and 36 weeks gestation. Term 
placentas were used as positive controls. This group performed qRT-PCR for 22 miRNAs 
that had been described previously as either being ‘pregnancy associated’ or ‘placental 
specific’ (the later group taken from the results of Liang et al. (2007)). Kotlabova et al. 
(2011) confirmed that only six of these 50 identified miRNAs were indeed placental 
specific and could be identified in maternal plasma at all three time points. These were 
the six miRNAs that we used – and the same primers were used as those described in the 
Kotlabova paper.    
 
 Two of the miRNA selected for this study (miR-517* and miR-526b) did not amplify in 
any of our specimens. This was the case even when cycling was increased to 50 cycles. 
This may be because they were not present in high enough concentrations in the sample 
(unlikely) or because of inefficiencies in the amplification protocol. Another explanation 
could be that there are ethnic variations in miRNA expression – although as the previous 
publication was conducted in central European population and as our own patients are 
predominantly European – this seems unlikely.  miR-526b did in fact show some 
variation within the Kotlabova paper and it may have been better to use the shorter 
primer miRNA-526a that was more consistent. It is also possible that these two miRNAs 
are placental tissue specific but are not always expressed in maternal plasma as had 
initially been thought.  
 
cel-miR-39 was used as to spike samples to act as a control for the efficiency of the qRT-
PCR and for normalization of the data. The strategy that should be followed to normalize 
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the data for biological variability is to use a miRNA that is not variable but that is 
endogenous to the sample. Currently such an endogenous miRNA hasn´t been identified 
(Tiberio et al. 2015). Studies done in cfmiRNA in cancer also use C.elegans as a spike 
control (Sita-Lumsden et al. 2013; Kroh et al. 2010). The lack of an internal control 
presents a problem in trying to define anomalies on the basis of variable miRNA 
expression. 
 
In the same set of experiments the remaining miRNAs (miR-516-5p, miR-518b, miR-
520a* and miR-525) including the spike in control (cel-miR-39) were detected at the 
expected cycle threshold. These miRNAs showed strong linear relationships between 
raw Ct-values and concentrations of small RNA determined by the Qubit, indicating that 
the primers and the probes worked as expected even without the use of the pre-
amplification step. In a similar manner the miRNAs post pre-amplification showed a 
similar linear relationship when investigated using a serial dilution. In all cases the pre-
amplified miRNA concentrations are significantly higher than the non-pre-amp samples 
even at the highest dilution. This demonstrates the utility of the pre-amplification step 
when investigating miRNA that is present in small quantities, such as cell-free-fetal 
miRNAs.  
 
In both stability experiments (at 4°C and Rt) there is high level of variability between 
samples at each time point. It would not be expected for different women to have the 
same levels of expression of miRNA. These natural levels of variability can by caused by 
potential confounding variables. Such as maternal age, gestational age, ethnicity etc. 
which were not possible to study in this cohort.  Cell contamination, the presence of 
protein and the presence of lipids can affect the efficiency of the isolation of miRNA 
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which can be the confounding variables(Sita-Lumsden et al. 2013). Also, individual 
factors can influence in the variability of the miRNA such as race, life-style, exercise, 
smoking habits, diet, gestational age and others (Tiberio et al. 2015). To account for this 
variability an average of the relative expression was used to compare the trends 
between tubes, miRNAs and times.  
 
miRNAs are known to be transported by various structures (microparticules, proteins, 
apoptotic bodies and multivesicular bodies to name a few) and released by trophoblasts 
and the shedding of placental cells (Kamhieh-Milz et al. 2014). These transported 
miRNAs can be found in maternal blood. For both of the experiments performed in this 
study, whole blood was stored and the plasma was separated at the time point of 
interest. The whole blood includes not just cell-free fetal nucleic acids but also the 
microparticles, white cells and platelets that can contain these nucleic acids. Over the 
time frame of these experiments these structures can break down and released 
additional miRNA into the plasma. Some white cells like neutrophils have a half life of 
approximately seven hours in the circulation (Blumenreich 1990), other structures that 
can release miRNAs are platelets, which have a half life of approximately four days 
(Cesar & Vecino 2009). For the other structures that can transport miRNA there is not 
much information of their half life but there is proof that these structures can help to 
maintain the integrity of miRNA and extend it´s half life (Cheng et al. 2014). This study 
shows in general that the amount of miRNA in the whole blood samples left either at 4°C 
or Rt increases with time. In this study this release is expressed as an increase towards 
the last time point, not just in the concentration but also in the standard deviation. This 
agrees with the theory that structures break down over time and release additional 
miRNA into the whole blood. The increase of the concentration is also reflected in the 
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relative expression of each miRNA. Interestingly despite this trend, higher expression is 
not observed in all the tube types or all the miRNAs being studied.  
 
In addition to the tubes we also showed that the relative expression of the miRNAs is 
changed with time and storage condition. For example miR-525 is fairly stable with 
time, while the relative expression of mir-516 and miR-520 increased over time, as does 
the variability of their measurement. A possible explanation for this could be the origin 
of the miRNAs. If mir-516 and miR-520 are present in different types of structures 
(microparticules, exososomes, cells and platelets), when the structures degraded the 
additional mir-516 and miR-520 is released into the whole blood. If miR-525 is only 
present as cell free miRNA or in some microparticles, there is little additional source for 
miR-525 to be released from. 
 
This experiment used three different types of tubes to collect the whole blood. The first 
two types of tubes, CITRATE and EDTA, have different compounds that are used for the 
same role, as anticoagulants. As such they stabilize whole blood allowing further 
investigation to be delayed to a later time. According to the literature CITRATE tubes 
have lower miRNA counts than EDTA tubes (Anon 2013a). Both tubes are designed to be 
stored at 4°C. In our study, the EDTA tubes that were stored at 4°C showed no significant 
change in miRNA concentrations over the course of the experiment. In contrast, tubes 
stored at Rt showed significant changes in miRNA concentrations indicating that miRNA 
levels are not stable in this circumstance. Based on the real time-PCR data the CITRATE 
tubes appeared to be more stable, but the strength of this conclusion has to be tempered 
by the fact that, due to the smaller sample size, only two time points could be assessed. 
The STRECK tubes are commercially prepared and specifically formulated for cell free 
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RNA stability. These tubes contain EDTA and nuclease inhibitors, metabolic inhibitors 
and a cell preservative in a liquid medium (Streck 2014). This is a proprietory product 
and the exact formulation of these materials is not provided. These additional 
preservatives are designed to improve the stability of cell-free RNA at Rt. This study 
showed that the samples stored in this tube were more stable at Rt compared to the 
samples at 4°C, as in studies done in cffDNA these types of tubes are useful for long 
periods of storages (Barrett et al. 2011; Wong et al. 2013). At Rt it takes three days 
before the concentration varies, while at 4°C after one day there is an increase. These 
generalized trends are seen in the three miRNA studied in this stability experiment, but 
the magnitude of the variability changes over time.   
 
The miRNA studied are according to the literature placental specific miRNA (Liang et al. 
2007; Kotlabova et al. 2011). In this study we detected that some of these miRNAs can 
also be measured in the circulation of non-pregnant women. In particular miR-525 was 
expressed in non-pregnant women albeit at much lower levels than detected in the 
circulation of pregnant women. On the other hand, the relative expression of miR-518 
and miR-520 was not different between the pregnant and non-pregnant women. The 
miRNAs which were not detected in the plasma of non-pregnant women are miR-516, 
miR-517* and miR-526b. Of these miRNAs only miR-516 was detected in pregnant 
women. Whether this miRNA is truly placental specific or merely only expressed in the 
circulation at very low concentrations is as yet not clear and requires further 
investigation.  
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5.2. Comparison of normal pregnancies to those with fetal abnormality 
In the time available for this project, relatively small numbers of fetal abnormality were 
seen in the clinical centre (Royal Prince Alfred Hospital). This included cohorts with 
chromosomal abnormality (predominantly Down syndrome), cardiac anomalies (a 
variety of defects) and neural tube defects (spina bifida or anencaphaly). The expression 
of these six miRNAs was compared between pregnancies carrying normal and abnormal 
fetuses.  
 
Most of these anomalous fetuses were detected through first trimester screening – and 
there is a significant difference in the gestational age of those that had trisomy 21 and 
the control samples – which could impact on miRNA expression. In addition, fetuses 
with Down syndrome typically have different nuchal translucency, free-BhCG and PaPP-
A levels. These differences are indicative of differences in cardiovascular physiology and 
placental function and changes in miRNA expression may merely be related to these 
factors rather than been novel independent variables that would be of additional value 
from a screening perspective. Neither the gestational age nor the first trimester 
screening features were so varied in the structural anomalies (compared to controls) 
and miRNA changes here may be a true representation of differing developmental 
regulation.   
 
Although there were no significant differences in miRNA expression between groups of 
abnormalities and controls, there was a difference in miR-520 expression in neural tube 
defects (NTD) – although this was only seen in CITRATE based samples. In these 
samples, miR-520 was down regulated compared to the control. It is not clear whether 
this is a ‘real’ result given the fact that only small numbers of samples affected by neural 
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tube defects were available and that there was a non-significant increase in miRNA-520 
expression in the EDTA and STRECK samples. This is the most extreme case of 
differences between tubes within a condition, but there is also indication that this sort of 
variance is present in other results. This indicates that care needs to be taken when 
selecting the type of tubes. More over, for miR-525, whilst not reaching statistical 
significance, there does appear to be down regulation between the neural tube defects 
(NTD), congenital heart defects (CHD) and controls. The data may become significant if 
greater numbers of cases were examined.  
 
As mentioned previously, when comparing the different types of condition 
(Chromosomal abnormalities, C-A, congenital heat defects, CHD and neural tube defects, 
NTD) with the control there are no significant change, however when the condition are 
divided into specific categories some variations start to emerge. The study made by Zhu 
et al. also shows that the expression of miRNA is different when comparing different 
types of CHD Vs controls, but not if the CHD are treated as a whole and are compared to 
the control (Zhu et al. 2013). We observed this in miR-525 in the C-A group, when 
looking at specific chromosomal-abnormalities, T21 is up regulated and T18 is down 
regulated.  This is also observed in miR-520 in the CHD group in which when looking at 
specific defects, HLHS is significantly different from the control group but when is 
analysed as a whole there is no significant differences. It is not possible to draw 
conclutions from this small study. However, the observation in this work and that oF 
Zhu et al. 2013  suggest larger studies are warranted.   
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5.3. Limitations of this study 
Whilst we have shown that we can isolate cell free fetal miRNA from maternal plasma, 
and have demonstrated that either STRECK tubes (at room temperature) or EDTA tubes 
(at 4°C) have minimal impact on stability of miRNA for a 48-72 hour period, there are 
some limitations in this study and in the potential applicability of this technology for 
prenatal diagnosis. 
 
One of the main disadvantages of this study is the use of qRT-PCR as a discovery tool for 
markers to identify different congenital abnormalities. qRT-PCR is generally used as a 
method for validation, due to the limited amount of miRNAs that can be studied. 
Microarrays or next generation sequencing can help in the discovery of new markers for 
each of the different abnormalities studied (Git et al. 2010) by analysing a wide range of 
miRNA in a single experiment.  More over, the miRNA analysed in this study can help 
more in the identification of problems with placental function than in the identification 
of congenital abnormalities, for example miR-518b that was elevated in pre-eclamptic 
placentas compared to normal placentas (Zhu et al. 2009).  
 
Another limitation of this study is the use of cel-miR-39 as a control for normalization of 
the data instead of an endogenous control that could correct for the biological 
variability. All though, as mentioned before there is not an endogenous control for 
plasma/serum samples, so the use of cel-miR-39 is necessary to correct for the efficiency 
of the qRT-PCR (Tiberio et al. 2015). Also, the scope of the study was limited by the 
number of samples for each condition collected over the course of this work. The 
acquisition of more samples would have allowed the confirmation of these findings and 
will give more statistical power to the conclusion.  
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Furthermore, a second or third centrifugation of the plasma was not done; this could 
affect the isolation of miRNA due to the contamination of platelets and white cells that 
can cause the presence of proteins, that can inhibit the efficiently of the extraction 
protocol or the qRT-PCR (Tiberio et al. 2015). Additionally, the collection and processing 
of additional samples post delivery or termination of pregnancy would have allow us to 
have more information to confirm that the miRNAs studied were truly placental specific 
miRNAs - as some other studies in the literature have done (Gu et al. 2012). 
 
Another factor that was not analysed in this study is the effect of the collection of the 
samples post CVS, which can increase the amount of miRNA found in circulation due to 
the invasive procedure done to the placenta. This has been analysed in cffDNA where 
there wasn´t a significant difference between the analysis of maternal plasma following 
CVS compared to maternal plasma prior to CVS (Di Tommaso et al. 2013).  
5.4. Future studies 
This study is the first approach in the identification placental specific miRNA that could 
one day, be used as a biomarker to assist in the detection of different congenital 
abnormalities. In addition they may add to a better understanding of the role that 
particular miRNAs play in congenital abnormalities. Thorough investigation should be 
undertaken so abnormalities can be detected earlier in pregnancy and more informed 
decisions about the course of a pregnancy could be taken.  
 
First of all there is the need for a larger number of samples for each type of congenital 
abnormality. The collection of these samples will be probably taken in different sites, 
 86 
which means that all samples will have to be processed at the same time points 
regardless of the distance that the samples have to travel, samples will have to be 
processed with in three days.   
 
Samples of blood for each type of congenital abnormality should be collected after first 
trimester screening if the pregnant women is part of the high risk group and another 
blood sample should be taken after the confirmation of the abnormalities (after CVS or 
Amniocentesis). These pre and post blood samples will allow us to confirm if there is a 
influence in the amount and relative expression of miRNAs caused by the invasive 
diagnosis, in a similar manner to the work done in cffDNA (Di Tommaso et al. 2013) . 
More over, it would be beneficial to have a blood bank of samples that are collected 
before the first trimester screening to be analysed if the fetus is diagnosed with an 
abnormality in a later stage. These samples will help us to determine if the miRNA 
identified as biomarkers for a specific abnormality can also be detected early in 
pregnancy.  
 
For all patients included in this future study, (pregnancies with normal and abnormal 
fetuses) samples of blood after delivery or termination should be taken. This step will 
help us to determine if the miRNA identified as biomarkers are truly specific to the fetus 
or not, this was performed by Gu et al. in the identification of miRNA in NTD and the 
miRNA selected as biomarkers were not present in maternal circulation after a couple of 
hours (Gu et al. 2012). Is also important to confirm if the miRNA being investigated are 
present or not in a large cohort of non-pregnant women, which will allow us to confirm 
the findings as abnormality specific miRNA.  
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In addition to blood samples, placental tissue would be collected after the delivery or 
termination. Further more the amniotic fluid and the chorionic villi would be collected 
after testing. These extra samples will test the robustness of these markers. This has 
been done in previous studies in which the detection in blood of some miRNA are not 
confirmed to be in the placenta or vice-versa (Liang et al. 2007; Kotlabova et al. 2011). 
 
For the processing of the all the different types of samples collected, miRNA would be 
isolated. Some of the blood samples collected from different types of abnormalities after 
diagnosis and some controls will be sequenced to detect the differentially express 
miRNA between the samples. The findings will be validated by qRT-PCR of all the other 
types of samples collected (Git et al. 2010). After the identification of the miRNAs by the 
application of bioinformatics the pathways that the miRNA are involve in will be 
identified and analysed.  
 
Finally, if possible it will be interesting to investigate the different paths of the miRNAs 
identified in mouse models (Keck-Wherley et al. 2011; Krichevsky 2003). The study of 
mouse models embryos with abnormalities will also help us in the understanding of the 
development of some abnormalities, and in the identification of the regulation pathways 
that some of the miRNA can be involved during development.  
5.5. Conclusions 
Optimization studies suggest that either STECK (room temperature) or EDTA (4OC) 
tubes should be used and plasma should be extracted within 72 hours. To allow for 
standardisation of results, in further studies the type of tube and time to processing 
should be constant. 
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There appears to be significant variation in miRNA expression. This variation may make 
quantitative comparison between normal and abnormal conditions difficult. Some 
‘placental specific’ miRNAs could not be detected at all and others are expressed in non-
pregnant women. The two exceptions were miR-525 (increased expression in pregnant 
women) and miR-516 (not expressed in non-pregnant women).  
 
The largest cohort of the abnormal samples tested were the ones affected by trisomy 21. 
There was no obvious difference in miRNA expression in the six miRNAs used in this 
study between these chromosomally abnormal pregnancies and normal controls. There 
was evidence that miR-520 is upregulated in fetuses affected by hypoplastic left heart 
syndrome – but this is currently based on evidence in two affected cases. Examination of 
samples from larger cohorts with fetal abnormalities, paying attention to grouping by 
the specific nature of the anomaly, is needed. Further work (using array or sequencing 
based technologies) is needed to determine whether specific miRNA signatures can be 
ascribed to individual congenital anomalies.    
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